CA2386540A1 - Novel carbamates and ureas - Google Patents

Novel carbamates and ureas Download PDF

Info

Publication number
CA2386540A1
CA2386540A1 CA002386540A CA2386540A CA2386540A1 CA 2386540 A1 CA2386540 A1 CA 2386540A1 CA 002386540 A CA002386540 A CA 002386540A CA 2386540 A CA2386540 A CA 2386540A CA 2386540 A1 CA2386540 A1 CA 2386540A1
Authority
CA
Canada
Prior art keywords
amino
compound
carbamic acid
hexyl ester
acetylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002386540A
Other languages
French (fr)
Inventor
Tariq M. Rana
Seongwoo Hwang
Natarajan Tamilarasu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Medicine and Dentistry of New Jersey
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2386540A1 publication Critical patent/CA2386540A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/12Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06086Dipeptides with the first amino acid being basic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0815Tripeptides with the first amino acid being basic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to novel carbamates, ureas, and pharmaceutically acceptable salts thereof; compositions comprising the carbamate, urea, or a pharmaceutically acceptable salt thereof; and methods for treating or preventing cancer, inflammation, or a viral infection comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of the carbamate, urea, or pharmaceutically acceptable salt thereof.

Description

NOVEL CARBAMATES AND UREAS
This invention was made with government support under grant nos. AI45466 and AI01369 awarded by the National Institute of Health. The government has certain rights in the invention.
This application claims the benefit of U.S. Provisional Application No.
'60/157,646, filed October 4, 1999, which is incorporated herein by reference in its entirety.
FIELD OF THE INVENTION
The present invention relates to novel carbamates, ureas, and pharmaceutically acceptable salts thereof; compositions comprising the carbamate, urea, or a pharmaceutically acceptable salt thereof; and methods for treating or preventing cancer, inflammation, or a viral infection comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of the carbamate, urea, or pharmaceutically acceptable salt thereof.
2. BACKGROUND OF THE INVENTION
Protein-nucleic acid interactions are involved in many cellular functions, including transcription, RNA splicing, RNA maturation, telomere synthesis, and mRNA
translation. Molecules that can bind with high affinity to specific sequences of single- or double-stranded nucleic acids have the potential to interfere with these interactions in a controllable way, making them attractive tools for molecular biology and medicine. Nucleic acids, and in particular RNA, however, can fold into complex tertiary structures consisting of local motifs such as loops, bulges, pseudoknots and turns (Chastain, M.
&Tinoco, L, Jr.
(1991) Progress in Nucleic Acid Res.& Mol. Biol. 41:131-177; Chow, C. S. &
Bogdan, F.
M. (1997) Chemical Reviews 97:1489-1514), which are critical for protein-RNA
interactions (Weeks, K. M. & Crothers, D. M. (1993) Science 261:1574-1577).
The dependence of these interactions on the native three-dimensional structure of RNA makes it difficult to design synthetic agents with general, simple-to-use recognition rules analogous to those for the formation of double- and triple-helical nucleic acids.
Transcription of the HIV genome during virus replication shows distinct kinetic phases (see e.g., Feinberg et al.
(1986) Cell 46:807-817; Kim et al. (1989) J. Virol. 63:3708-3713; Knight et al. (1987) Science 236:837-840; Sodrowski et al. (1986) Nature (London) 321:412-417). The initial products of HIV gene expression are short, multiply spliced mRNAs approximately 1.8 to 2.0 kb in length, which encode the traps-acting regulatory proteins TAT, REV, and possibly NEF. As infection by the virus develops, and the levels of the TAT and REV
proteins rise in the infected cells, mRNA production shifts progressively towards production of a family of singly-spliced 4.3kb mRNAs encoding ENV and other HIV gene products such as VIF
and VPR. To achieve this control of gene expression, the HN virus relies on the interaction of cellular and virus-encoded traps-acting factors with cis-acting viral regulatory sequences (Dayton et al. (1986) Cell 44:941-947; Fisher et al. (1986) Nature 320:367-371; Feinberg et al. (1986) Cell 46:807-817). Initiation of transcription relies largely on the presence of binding sites for cellular transcription factors in the viral long terminal repeat (LTR) (Garcia et al. (1989) EMBO J. 8:765-778). The virally encoded regulatory proteins TAT
and REV
exert their activity via cis-acting sequences encoded within HN messenger RNAs. The traps activation-responsive region (TAR) is required for TAT activity, and is located in the viral long terminal repeat (LTR)between residues +1 and +79 (Muesing et al.
(1987) Cell 48:691-701; Emerman et al. (1987) EMBO J. 6:3755-3760; Roy et al. (1990) J
Virol.
64:1402-1406 (1990); Berkhout et al. (1989) .l. Yirol. 63:5501-5504).
The distinct kinetic phases of HN transcription are now believed to reflect the intracellular levels of the regulatory proteins TAT and REV. As TAT levels rise, increased transcription from the LTR is stimulated by the traps-activation mechanism. This leads to further increases in TAT levels, and also stimulates production of REV. Production of the viral structural proteins begins once REV levels have risen to sufficiently high levels to promote export of messenger RNAs carrying the rev-responsive element (RRE)sequence.
Significant levels of HIV gene expression are only achieved in the presence of TAT
protein. Experiments strongly suggest that TAT activity requires RNA target sequences.
Deletion analysis of the viral LTR showed that TAT activity requires a regulatory element located downstream of the initiation site for transcription, at the 5-terminus of all the mRNA transcripts between residues +1 and +79, called the traps-activation-response region (TAR) (Muesing et al. (1987) Cell 48:691-701; Emerman et al. (1987) EMBO J.
6:3755-3760; Roy et al. (1990) J Yirol. 64:1402-1406 (1990); Berkhout et al.
(1989) J.
Yirol. 63:5501-5504). The placement of TAR in a transcribed region suggested that it could function as an RNA rather than as a DNA element. (Muesing et al. (1987) Cell 48:691-701;
Emerman et al. (1987) EMBO J. 6:3755-3760; Selby et al. (1989) Genes Dev.
3:547-558;
Hauber et al. (1988) J. Yirol. 62:673-679; Jakobovits et al. (1988) J. Mol.
Cell Biol.
8:2555-2561; Peterlin et al. (1986) Proc. Natl. Acad. Sci. U.S.A. 83:9734-9738).

Furthermore, the TAR RNA sequence forms a highly stable, nuclease-resistant, stem-loop structure (Selby et al. (1989) Genes & Dev.
3:547-558). It appears that the TAR RNA sequence must be transcribed in the nucleus and correctly folded in order for trans-activation to occur (Berkhout (1989) Cell 59:273-282).
And it has been demonstrated that TAT is able to specifically recognize TAR
RNA. Binding shows high affinity (Kd =12 nM) and TAT forms one-to-one complexes with TAR RNA (Dingwall et al. (1990) EMBO J. 9:4145-4153). This provides strong evidence for the ability of TAT to stimulate transcription from promoters that carry the TAR
sequence by direct binding to TAR RNA. Compounds that bind TAR RNA inhibit the activity of the regulatory protein TAT in the viral growth cycle of HIV and, accordingly, are useful for treating or preventing HIV infection.
Moreover, compounds that bind to specific sequences and/or structures in nucleic acids and thereby modulate or interfere with protein-nucleic acids, and in particular, protein-RNA interactions, are potentially valuable therapeutic agents useful for the 1 S prevention and treatment of cancer, and inflammatory conditions, as well as disease arising from viral infection, including HN infection and AIDS.
Therefore, there is a clear need in the art for compounds that bind RNA and interfere with protein-RNA interactions, and in particular, there is a clear need in the art for compounds that bind TAR RNA.
Citation or identification of any reference in Section 2 of this application is not an admission that such reference is available as prior art to the present invention.
3. SUMMARY OF THE INVENTION
The present invention provides compounds of formula I:

and pharmaceutically acceptable salts thereof, wherein each Y is independently a radical having the structure of II, III, or IV:

(CHz)m ~ (CHZ)m O
* ~ H m ~ ~N
( ~ z) O or H
O ' R1 ' O
II III IV
each R, is independently selected from the group consisting of -NHz, -NHC(=NH)NHZ, and -CHZC(=NH)NHZ;
each m is independently an integer ranging from 3 to 7;
each * is an (R) or (S) chiral center; and with the proviso that at least one Y is a radical having the structure of IV.
In one embodiment, the compounds of formula I and pharmaceutically acceptable salts thereof are those wherein at least two Y are independently a radical having the structure of N.
In another embodiment, the compounds of formula I and pharmaceutically acceptable salts thereof are those wherein each Y is independently a radical having the structure of N.
The compounds of formula I and pharmaceutically acceptable salts thereof are useful for treating or preventing cancer, inflammation, or a viral infection in a patient.
The present invention further provides compositions comprising a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof. The compositions comprising a compound of formula I
or a pharmaceutically acceptable salt thereof can additionally comprise a pharmaceutically acceptable vehicle. These compositions are useful for treating or preventing cancer, inflammation, or a viral infection in a patient.
The present invention still further provides a method for treating or preventing cancer, inflammation, or a viral infection in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof.
The present invention still further provides compounds of formula V:
Rz R2 O (CHz)n O (CHz)n H H
* N N * * NHz HZN N ~ \N N
H H H
O ( ~ Hz)n Rz V
and pharmaceutically acceptable salts thereof, wherein each RZ is independently selected from the group consisting of -NH2, -NHC(=NH)NHZ, -CHzC(=NH)NH2, and -C(O)NH2;
each n is independently an integer ranging from 3 to 7; and each * is an (R) or (S) chiral center.
The compounds of formula V and pharmaceutically acceptable salts thereof are useful for treating or preventing cancer, inflammation, or a viral infection in a patient.
The present invention still further provides compositions comprising a therapeutically effective amount of a compound of formula V or a pharmaceutically acceptable salt thereof. The compositions comprising a compound of formula V
or a pharmaceutically acceptable salt thereof can additionally comprise a pharmaceutically acceptable vehicle. These compositions are useful for treating or preventing cancer, inflammation, or a viral infection in a patient.
The present invention still further provides a method for treating or preventing cancer, inflammation, or a viral infection in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of formula V or a pharmaceutically acceptable salt thereof.
The present invention may be understood more fully by reference to the figures, detailed description, and examples, which are intended to exemplify non-limiting embodiments of the invention.
4. BRIEF DESCRIPTION OF THE FIGURES
Fig. 1 is a schematic depiction of a synthesis of a carbamate monomer useful for installing the radical having the structure IV in the compounds of formula I. R, is -NHz,-NHC(=NH)NHZ, or -CHzC(=NH)NH2. m is an integer ranging from 3 to 7.
Fig. 2 is a schematic depiction of a general method for synthesizing momoners useful for synthesizing the compounds of formula V. R2 is -NHz, -NHC(=NH)NH2, or -CHzC(=NH)NHz. n is an integer ranging from 3 to 7.
Fig. 3 is a schematic depiction of a synthesis of Compound AU.
Fig. 4 and Fig. S show a synthesis of Compound DW.
5. DETAILED DESCRIPTION OF THE INVENTION
5.1 DEFINITIONS AND ABBREVIATIONS
"HMBA" is 4-(2',4'-dimethoxyphenyl-Fmoc aminomethyl)-phenoxyacetamido-norleucyl-methylbenzhydrylamine resin.
"Mtr" is a (4-methoxy-2,3,6-trimethylphenyl)sulfonyl group.
"tBOC" and "BOC" are t-butoxycarbonyl groups.
"Fmoc" is a 9-fluorenylmethoxycarbonyl protecting group.
"Teoc-ONP" is 2-(trimethylsilyl)ethyl-4-nitrophenyl carbonate.
1 S "MsCI" is methanesulfonyl chloride.
"TEA" is triethylamine.
"DIPEA" is diisopropylethylamine.
"TIPS" is trisisopropylsilane.
"TFA" is trifluoroacetic acid.
"THF" is tetrahydrofuran.
"TBAF" is tetrabutylammonium fluoride.
"HOBT" is 1-hydroxybenzotriazole.
"DIPDCI" is 1,3-diisopropyldicarboimide.
"NMP" is N-methylpyrrolidinone.
"DMF" is N,N-dimethylformamide.
As used herein, the term "compounds of the invention" means, collectively, the compounds of formula I, formula V, pharmaceutically acceptable salts thereof.
The compounds of the invention are identified herein by their chemical structure and/or chemical name. Where a compound is referred to by both a chemical structure and a chemical name, and that chemical structure and chemical name conflict, the chemical structure is determinative of the compound's identity.
The compounds of the invention contain one or more chiral centers, depicted by an asterisk (*) in formula I and formula V and by a bold or dashed line in compounds specific to formula I or formula V. Therefore, the compounds of the invention exist as enantiomers or diastereomers. According to the invention, formula I and formula V
encompass all of the corresponding compounds' enantiomers, i.e., each (+)- and (-)-enantiomer, and diastereomers, i.e., each chiral center's (R) and (S) isomer.
(R) and (S) assignments are made according to well-known sequence-rule procedures for determining (R) and (S) priority (see, for example, IUPAC Nomenclature of Organic Chemistry, Section E (1979); R.S. Cahn et al., Angew. Chem. 78:413-447 (1966); and V. Prelog et al., Angew.
Chem., Int. Ed., 21:567-583 (1982)).
In the compounds of formula I, and pharmaceutically acceptable salts thereof, each radical having the structure of II, III, or IV binds as written from left to right to H-, II, III, IV, or -NH2, as the case may be.
As used herein, the term "patient" means an animal, including, but not limited, to an animal such a cow, monkey, horse, sheep, pig, chicken, turkey, quail, cat, dog, mouse, rat, rabbit, and guinea pig, and is more preferably a mammal, and most preferably a human.
When administered to a patient, e.g., an animal for veterinary use or for 1 S improvement of livestock, or to a human for clinical use, the compounds of the invention are administered in isolated form. As used herein, "isolated" means that the compounds of the invention are separated from other components of either (a) a natural source, such as a plant or cell, preferably bacterial culture, or (b) a synthetic organic chemical reaction mixture. Preferably, via conventional techniques, the compounds of the invention are purified. As used herein, "purified" means that when isolated, the isolate contains at least 95%, preferably at least 98%, by weight, of a particular enantiomer, racemate, or diastereomer of a compound of formula I or formula V.
As used herein, the phrase "pharmaceutically acceptable salt(s)," means salts) formed from an acid and a primary, secondary, or tertiary amino group of a compound of formula I or formula V. Preferred salts include, but not limited, to sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate,p-toluenesulfonate, and pamoate (i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)) salts.
5.2 SYNTHESIS OF THE COMPOUNDS OF THE INVENTION
The compounds of the invention can be obtained via conventional organic synthesis, preferably on a solid support. Generally, in a process well known to those of _7_ ordinary skill in the art, activated monomers are introduced to and bound by reactive moieties on the solid support, or to linker molecules attached to the support.
After introduction, the first monomer is completely coupled to substantially all the sites of the solid support. Complete coupling means that the coupling reaction is driven to completion irrespective of the differences in the coupling rates of individual monomeric units to be attached. In addition, the monomers are coupled to substantially all available coupling sites on the solid support so that each solid support will contain essentially only one molecular species.
The coupling of the monomers to the support may be accomplished by techniques familiar to those in the art and as provided below as well as, for example, in Stewart and Young, 1984, Solid Phase Synthesis, Second Edition, Pierce Chemical Co., Rockford, IL.
As would be known to those of ordinary skill in the art, the process of synthesis on solid supports generally involves building an oligomeric or polymeric compound, proceeding from one defined and activated end. After attachment of the first monomeric unit to the solid support, the protecting groups) are then cleaved off, and the next monomer, also protected, is coupled to the first monomer attached to the solid support. The cycle of deprotection and coupling is repeated until the oligomeric compound is completed. Any reactive side chains are protected by chemical groups that can withstand the coupling and deprotection procedure but can be removed at the end of the synthesis.
In order to couple each monomeric unit to the growing synthetic chain, one reactive moiety of the protected monomer must be activated. Many methods of activation may be used in the practice of the invention and include, for example, preformed symmetrical anhydrides (PSA), preformed mixed anhydride (PMA), acid chlorides, active esters, and in situ activation, as set forth in Fields and Noble, 1990, "Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids", Int. J. Pept. Protein Res.
35:161-214.
The use of Fmoc amino acids is but one strategy of peptide synthesis. A Boc (t-butyloxycarbonyl-protected amino group) strategy may also be used to prepare a library of peptides bound to the solid support (e.g., Geysen et al., 1987, J. Immunol.
Methods 102:259-274).
5.2.1 THE COMPOUNDS OF FORMULA I
The compounds of formula I and pharmaceutically acceptable salts thereof are carbamates and can be obtained via conventional methods (see, for example, S.J. Paikoff et al., Tetrahedron Lett. 37(32):5653-5656 (1996) and C.Y. Cho et al., Science 261:1303-1305 (1993)).
_g_ The radical having the structure IV can be installed in the compounds of formula I using a carbamate monomer 3 (Fig. 1). The carbamate monomers preferably have an Fmoc protecting group. The carbamate monomers are those wherein R, is -NH2, -NHC(=NH)NHz, or -CHzC(=NH)NHZ; and m is an integer ranging from 3 to 7.
Carbamate monomers 3 can be obtained from N"-Fmoc-protected amino acids 1. N"-Fmoc-protected amino acids are available commercially, for example, from Aldrich Chemical Co.
Milwaukee, WI or by using known synthetic methods, for example, by those described in Carpino et al., J. Org. Chem. 37:3404 (1972). N"-Fmoc-protected amino acids 1 can be reduced to their corresponding amino alcohols 2 using, for example, N-methyl morpholine ~d isobutyl chloroformate, followed by treatment with NaBH4. Amino alcohols 2 are then activated using 4-nitrophenylchloroformate to provide carbamate monomers 3, which can be purified using conventional silica gel chromatography.
Preferred compounds of formula I are:

Carbamic acid 6-amino-2-[6-amino-2-(2,6-diamino-hexyloxycarbonylamino)-hexyloxycarbonylamino]-hexyl ester (Compound AA);
NHz NHz = H O
HzN~/O~N ~N~O~NHz ]°~ H ~o NHz Carbamic acid 6-amino-2-[6-amino-2-(2,6-diamino-hexyloxycarbonylamino)-hexyloxycarbonylamino]-hexyl ester . (Compound AB);

H O
H N N ~N~/O~NH2 z ~"
O H O

Carbamic acid 6-amino-2-[6-amino-2-(2,6-diamino-hexanoylamino)-hexyloxycarbonylamino]-hexyl ester (Compound AC);
NHz NHz H O[~
H2N~N O~N~/O~NHz IO H I IO
NHz Carbamic acid 6-amino-2-[6-amino-2-(2,6-diamino-hexanoylamino)-hexyloxycarbonylamino]-hexyl ester (Compound AD);

H O _ HN~N ~N~O~NH2 O H I IO

Carbamic acid 6-amino-2-{6-amino-2-[2-(5-amino-pentylamino)-acetylamino]-hexyloxycarbonylamino}-hexyl ester (Compound AE);

H
Carbamic acid 6-amino-2-{6-amino-2-[2-(7-amino-heptylamino)-acetylamino]-hexyloxycarbonylamino}-hexyl ester (Compound AF);

H O
HN~N O~N~O~NH2 O H IOI

Carbamic acid 6-amino-2-{6-amino-2-[2-(4-amino-butylamino)-acetylamino]-hexyloxycarbonylamino}-hexyl ester (Compound AG);

~O~NH2 H2 ~N
O
Carbamic acid 6-amino-2-[6-amino-2-(2-amino-5-guanidino-pentyloxycarbonylamino)-hexyloxycarbonylamino]-hexyl ester (Compound AH);

NHz O NHz O
= H ~~
HzN~/O~N ~N~/O~NHZ
O H O
NHZ
Carbamic acid 6-amino-2-[6-amino-2-(2-amino-4-carbamoyl-butoxycarbonylamino)-hexyloxycarbonylamino]-hexyl ester (Compound AI);

H p _ H2N O~N~~N~O~NH2 O H O

Carbamic acid 6-amino-2-[6-amino-2-(2,6-diamino-hexyloxycarbonylamino)-hexyloxycarbonylamino]-hexyl ester (Compound AJ);

= H O _ HZN~O~Ny/~p~N~O~NH2 IOI H I IO
NHZ
Carbamic acid 6-amino-2-[6-amino-2-(2,6-diamino-hexyloxycarbonylamino)-hexyloxycarbonylamino]-hexyl ester (Compound AK);

NH2 NHz H O
H N N~p~N~O~NHz z O H O
NHz Carbamic acid 6-amino-2-[6-amino-2-(2,6-diamino-hexanoylamino)-hexyloxycarbonylamino]-hexyl ester (Compound AL);
NHz NH2 H O =
H N N~O~N~O NHz 2 ~ H
NHz Carbamic acid 6-amino-2-[6-amino-2-(2,6-diamino-hexanoylamino)-hexyloxycarbonylamino]-hexyl ester (Compound AM);
NHz H O _ HN N~p~N~O~NHz H O

Carbamic acid 6-amino-2-{6-amino-2-[2-(5-amino-pentylamino)-acetylamino]-hexyloxycarbonylamino}-hexyl ester (Compound AN);

H O _ $ HN~N~O~N~/O~NH2 O H ~O

Carbamic acid 6-amino-2-{6-amino-2-[2-(7-amino-heptylamino)-acetylamino]-hexyloxycarbonylamino}-hexyl ester (Compound AO);

H O _ HN N~p~N~O~NH2 H O

Carbamic acid 6-amino-2-{6-amino-2-[2-(4-amino-butylamino)-acetylamino]-hexyloxycarbonylamino}-hexyl ester (Compound AP);
HN \ /NHz NHz NH
H O _ 3O H N O~N~~N~O~NH2 ~z O H O
NHz Carbamic acid 6-amino-2-[6-amino-2-(2-amino-S-guanidino-pentyloxycarbonylamino)-hexyloxycarbonylamino]-hexyl ester (Compound AQ);

NHz O
- H u H2N~/O~N~O~N~/O~NHz IOI H I IO

Carbamic acid 6-amino-2-[6-amino-2-(2-amino-4-carbamoyl-butoxycarbonylamino)-hexyloxycarbonylamino]-hexyl ester (Compound AR);

O\ /NH2 H2N N ~~
H O
Carbamic acid 6-amino-2-{2-[(4-amino-butyl)-(2,6-diamino-hexyloxycarbonyl)-amino]-acetylamino}-hexyl ester (Compound AS);

O
~~ -H2N~O~N~N~O~NH2 ~O H ~''~O
Carbamic acid 6-amino-2-{2-[(4-amino-butyl)-(2,6-diamino-hexyloxycarbonyl)-amino]-acetylamino}-hexyl ester (Compound AT);

O
H N N~N~O NH2 H
Carbamic acid 6-amino-2-{2-[(4-amino-butyl)-(2,6-diamino-hexanoyl)-amino]-acetylamino}-hexyl ester (Compound AU);

O -H N N~N~O NH2 O H O
Carbamic acid 6-amino-2-{2-[(4-amino-butyl)-(2,6-diamino-hexanoyl)-amino]-acetylamino}-hexyl ester (Compound AV);

O
HN N~N~O NH2 H

Carbamic acid 6-amino-2-(2-{(4-amino-butyl)-[2-(4-amino-butylamino)-acetyl]-amino}-acetylamino)-hexyl ester (Compound AW);

$ HN ~N~/O~NH2 l H ~O

Carbamic acid 6-amino-2-(2-{(4-amino-butyl)-[2-(7-amino-heptylamino)-acetyl]-amino}-acetylamino)-hexyl ester (Compound AX);

O
HN N~N~O NH2 ~ H
NHz Carbamic acid 6-amino-2-(2-{(4-amino-butyl)-[2-(4-amino-butylamino)-acetyl]-amino}-acetylamino)-hexyl ester (Compound AY);

um mu_ H2N ~N~/O NH2 H
O
Carbamic acid 6-amino-2-{2-[(4-amino-butyl)-(2-amino-5-guanidino-pentyloxycarbonyl)-amino]-acetylamino}-hexyl ester (Compound AZ);

= O
H2N j~0 N~N~O NH2 H
Carbamic acid 6-amino-2-{2-[(4-amino-butyl)-(2-amino-4-carbamoyl-butoxycarbonyl)-amino]-acetylamino}-hexyl ester (Compound BA);

O
H N O N~N~O NH2 H
Carbamic acid 6-amino-2-{2-[(5-amino-pentyl)-(2,6-diamino-hexyloxycarbonyl)-amino]-acetylamino}-hexyl ester (Compound BB);

. o H2N~O~N~N~O~NH2 O~ H ~O
Carbamic acid 6-amino-2-{2-[(5-amino-pentyl)-(2,6-diamino-hexyloxycarbonyl)-amino]-acetylamino}-hexyl ester (Compound BC);

O
H N N~N~O NH2 H
Carbamic acid 6-amino-2-}2-[(S-amino-pentyl)-(2,6-diamino-hexanoyl)-amino]-acetylamino}-hexyl ester (Compound BD);

O
H N N~N~O NH2 2 ~ H
Carbamic acid 6-amino-2- f 2-[(5-amino-pentyl)-(2,6-diamino-hexanoyl)-amino]-acetylamino}-hexyl ester (Compound BE);

H N~
H O
Carbamic acid 6-amino-2-(2-{(5-amino-pentyl)-[2-(5-amino-pentylamino)-acetyl]-amino~-acetylamino)-hexyl ester (Compound BF);

O' /NH2 HN N ~~
~ H O

Carbamic acid 6-amino-2- f 2-[[2-(7-amino-heptylamino)-acetyl]-(5-amino-pentyl)-amino]-acetylamino~-hexyl ester (Compound BG);

O
HN N~N~O NH2 H
O

Carbamic acid 6-amino-2-{2-[[2-(4-amino-butylamino)-acetyl]-(5-amino-pentyl)-amino]-acetylamino}-hexyl ester (Compound BH);
HN \ /NH2 NH2 NH2 ~N H
O
H2N 0 N~N~/O NH2 ~ H
Carbamic acid 6-amino-2-{2-[(2-amino-5-guanidine-pentyloxycarbonyl)-(S-amino-pentyl)-amino]-acetylamino{-hexyl ester (Compound Bn;

O
H2N j~0 N~N~O NH2 ~ H
Carbamic acid 6-amino-2-{2-[(2-amino-4-carbamoyl-butoxycarbonyl)-(5-amino-penty1)-amino]-acetylamino}-hexyl ester (Compound BJ);

O
H N O N~N~/O NH2 H
Carbamic acid 6-amino-2-{2-[(7-amino-heptyl)-(2,6-diamino-hexyloxycarbonyl)-amino]-acetylamino}-hexyl ester (Compound BK);

O
H2N~0 N~N~O NH2 H
Carbamic acid 6-amino-2-{2-[(7-amino-heptyl)-(2,6-diamino-hexyloxycarbonyl)-amino]-acetylamino}-hexyl ester (Compound BL);

H2N~N~N~O~NH2 Carbamic acid 6-amino-2-{2-[(7-amino-heptyl)-(2,6-diamino-hexanoyl)-amino]-acetylamino}-hexyl ester (Compound BM);

O -H N N~N~O NH2 H
Carbamic acid 6-amino-2-{2-[(7-amino-heptyl)-(2,6-diamino-hexanoyl)-amino]-acetylamino}-hexyl ester (Compound BN);

HN ~O~NHZ
l o Carbamic acid 6-amino-2-(2- f (7-amino-heptyl)-[2-(5-amino-pentylamino)-acetyl]-amino}-acetylamino)-hexyl ester (Compound BO);

NHZ

O
HN N~N~O NH2 H

Carbamic acid 6-amino-2-(2-{(7-amino-heptyl)-[2-(7-amino-heptylamino)-acetyl]-amino}-acetylamino)-hexyl ester (Compound BP);
NHZ

O
HN N~N~O NH2 H
NHZ
Carbamic acid 6-amino-2-{2-[[2-(4-amino-butylamino)-acetyl]-(7-amino-heptyl)-amino]-acetylamino}-hexyl ester (Compound BQ);

H N~V~rv~Nwyvn2 j'[2 Carbamic acid 6-amino-2-{2-[(2-amino-5-guanidino-pentyloxycarbonyl)-(7-amino-heptyl)-amino]-acetylamino}-hexyl ester (Compound BR);

O
H NCO N~N~O NH2 Carbamic acid 6-amino-2-{2-[(2-amino-4-carbamoyl-butoxycarbonyl)-(7-amino-heptyl)-amino]-acetylamino}-hexyl ester (Compound BS);

H O -H N O~N~N~O~NH2 O H O

Carbamic acid 6-amino-2-[6-amino-2-(2,6-diamino-hexyloxycarbonylamino)-hexanoylamino]-hexyl ester (Compound BT);

H O _ H2N~O~N~N~O~NH2 ~O H ~O

Carbamic acid 6-amino-2-[6-amino-2-(2,6-diamino-hexyloxycarbonylamino)-hexanoylamino]-hexyl ester (Compound BU);

H O
H N N~N~O NH2 H

Carbamic acid 6-amino-2-[6-amino-2-(2,6-diamino-hexanoylamino)-hexanoylamino]-hexyl ester (Compound BV);

H O
H N N~N~O NH2 2 ~ H

Carbamic acid 6-amino-2-[6-amino-2-(2,6-diamino-hexanoylamino)-hexanoylamino]-hexyl ester (Compound BW);

H O
HN N~N~O NH2 H
NHZ

Carbamic acid 6-amino-2-{6-amino-2-[2-(5-amino-pentylamino)-acetylamino]-hexanoylamino}-hexyl ester (Compound BX);

H O
HN N~N~O NH2 H
NHZ

Carbamic acid 6-amino-2-{6-amino-2-[2-(7-amino-heptylamino)-acetylamino]-hexanoylamino)-hexyl ester (Compound BY);

NHZ
H O
HN N~N~O NH2 H

rbamic acid 6-amino-2-{6-amino-2-[2-(4-amino-butylamino)-acetylamino]-hexanoylamino}-hexyl ester (Compound BZ);

H
O~N HZ
H2 ~'[N
O
Carbamic acid 6-amino-2-[6-amino-2-(2,6-diamino-hexyloxycarbonylamino)-hexyloxycarbonylamino]-hexyl ester (Compound CA);

O' /NHp H2 ~N
O
Carbamic acid 6-amino-2-[6-amino-2-(2,6-diamino-hexyloxycarbonylamino)-hexyloxycarbonylamino]-hexyl ester (Compound CB);

H O
H N N ~N O~NH2 O H O

Carbamic acid 6-amino-2-[6-amino-2-(2,6-diamino-hexanoylamino)-hexyloxycarbonylamino]-hexyl ester (Compound CC);

O
H II
H N N ~N O NH2 H

Carbamic acid 6-amino-2-[6-amino-2-(2,6-diamino-hexanoylamino)-hexyloxycarbonylamino]-hexyl ester (Compound CD);
NHS
H

HN
I IO
NH2 ' Carbamic acid 6-amino-2-{6-amino-2-[2-(5-amino-pentylamino)-acetylamino]-hexyloxycarbonylamino}-hexyl ester (Compound CE);

H O
HN II N ~N O II NH2 O H O

Carbamic acid 6-amino-2-{6-amino-2-[2-(7-amino-heptylamino)-acetylamino]-hexyloxycarbonylamino}-hexyl ester (Compound CF);

H O
HN~N "N O~NH2 O H 'I0 Carbamic acid 6-amino-2-{6-amino-2-[2-(4-amino-butylamino)-acetylamino]-hexyloxycarbonylamino}-hexyl ester (Compound CG);
HN \/NH2 NHZ
NH
H O
HZN ~N ' _N O~NHZ
O H O
NHZ
Carbamic acid 6-amino-2-[6-amino-2-(2-amino-5-guanidino-pentyloxycarbonylamino)-hexyloxycarbonylamino]-hexyl ester (Compound CH);

O NHz HzN~/O
O
Carbamic acid 6-amino-2-[6-amino-2-(2-amino-5-guanidino-pentyloxycarbonylamino)-hexyloxycarbonylamino]-hexyl ester (Compound CI);
NH2 NHz H O
1S H2N O~N~~N O\ /NHZ
]'O~ H ~O
NHz Carbamic acid 6-amino-2-[6-amino-2-(2,6-diamino-hexyloxycarbonylamino)-hexyloxycarbonylamino]-hexyl ester (Compound CJ);
NHZ NHz . H
H2N~o~N~~N O~NHZ
~O H ~'[O
NHz Carbamic acid 6-amino-2-[6-amino-2-(2,6-diamino-hexyloxycarbonylamino)-hexyloxycarbonylamino]-hexyl ester (Compound CK);

H O
H N N~O~N O~NHz IIz O H O
NHz Carbamic acid 6-amino-2-[6-amino-2-(2,6-diamino-hexanoylamino)-hexyloxycarbonylamino]-hexyl ester (Compound CL);
N-H
N NHz I IO
NHz Carbamic acid 6-amino-2-[6-amino-2-(2,6-diamino-hexanoylamino)-hexyloxycarbonylamino]-hexyl ester (Compound CM);
N Hz H O
HN~N~O~N O~NH2 ICI H
NHz NHz Carbamic acid 6-amino-2-{6-amino-2-[2-(S-amino-pentylamino)-acetylamino]-hexyloxycarbonylamino}-hexyl ester (Compound CN);

H O
HN~N~O~N O~NH2 IOI H I IO

Carbamic acid 6-amino-2- f 6-amino-2-[2-(7-amino-heptylamino)-acetylamino]-hexyloxycarbonylamino}-hexyl ester (Compound CO);

H O
HN~N~O~N O~NH2 IOI H I IO

Carbamic acid 6-amino-2- f 6-amino-2-[2-(4-amino-butylamino)-acetylamino]-hexyloxycarbonylamino}-hexyl ester (Compound CP);
HN \ /NH2 NH
H O
HZN O~N~p~N O\ /NHZ
~O H ~O

Carbamic acid 6-amino-2-[6-amino-2-(2-amino-5-guanidino-pentyloxycarbonylamino)-hexyloxycarbonylamino]-hexyl ester (Compound CQ);

O
= H ~J
S H2N~/O~N~O~H O~NH2 IOI I IO
NHZ
Carbamic acid 6-amino-2-[6-amino-2-(2-amino-4-carbamoyl-butoxycarbonylamino)-hexyloxycarbonylamino]-hexyl ester (Compound CR);

H~ NHS
Carbamic acid 6-amino-2-{2-[(4-amino-butyl)-(2,6-diamino-hexyloxycarbonyl)-amino]-acetylamino}-hexyl ester (Compound CS);

H2N~0 N~N O NH2 H
Carbamic acid 6-amino-2-{2-[(4-amino-butyl)-(2,6-diamino-hexyloxycarbonyl)-amino]-acetylamino}-hexyl ester (Compound CT);

O
H2N N~N H2 O H
Carbamic acid 6-amino-2- f 2-[(4-amino-butyl)-(2,6-diamino-hexanoyl)-amino]-acetylamino}-hexyl ester (Compound CU);

O
H2N N~N H2 H
O
Carbamic acid 6-amino-2- f 2-[(4-amino-butyl)-(2,6-diamino-hexanoyl)-amino]-acetylamino}-hexyl ester (Compound CV);
H~ NHS
HN ~N H2 l H

Carbamic acid 6-amino-2-(2- f (4-amino-butyl)-[2-(5-amino-pentylamino)-acetyl]-amino}-acetylamino)-hexyl ester (Compound CW);

NHZ NHS
O
. H N N v 'N H2 H
O

Carbamic acid 6-amino-2-(2- f (4-amino-butyl)-[2-(7-amino-heptylamino)-acetyl]-amino}-acetylamino)-hexyl ester (Compound CX);

O
HN NV \N H2 H
O

Carbamic acid 6-amino-2-(2-{(4-amino-butyl)-[2-(4-amino-butylamino)-acetyl]-amino}-acetylamino)-hexyl ester (Compound CY);
HN \ /NH2 NH
O
H N O~N~N O\ /NH2 ~2 O H O
Carbamic acid 6-amino-2-{2-[(4-amino-butyl)-(2-amino-5-guanidino-pentyloxycarbonyl)-amino]-acetylamino}-hexyl ester (Compound CZ);

NHS NHS

O
H NCO N~N H2 O H
Carbamic acid 6-amino-2-{2-[(4-amino-butyl)-(2-amino-4-carbamoyl-butoxycarbonyl)-amino]-acetylamino}-hexyl ester (Compound DA);

O
O N~ O NH2 H2N ~ H
Carbamic acid 6-amino-2-{2-[(S-amino-pentyl)-(2,6-diamino-hexyloxycarbonyl)-amino]-acetylamino}-hexyl ester (Compound DB);

O
H2N~0 N~N O NH2 ~ H
Carbamic acid 6-amino-2-{2-[(5-amino-pentyl)-(2,6-diamino-hexyloxycarbonyl)-amino]-acetylamino{-hexyl ester (Compound DC);

O
u H2N N~N H2 O H
Carbamic acid 6-amino-2-{2-[(5-amino-pentyl)-(2,6-diamino-hexanoyl)-amino]-acetylamino}-hexyl ester (Compound DD);

O
H N N~N O NH2 H
Carbamic acid 6-amino-2-{2-[(5-amino-pentyl)-(2,6-diamino-hexanoyl)-amino]-acetylamino}-hexyl ester (Compound DE);

O
HN N~N O NH2 H

Carbamic acid 6-amino-2-(2-{(5-amino-pentyl)-[2-(5-amino-pentylamino)-acetyl]-amino}-acetylamino)-hexyl ester (Compound DF);

NHS
O

HN N~N H
H
O

Carbamic acid 6-amino-2- f 2-[[2-(7-amino-heptylamino)-acetyl]-(5-amino-pentyl)-amino]-acetylamino}-hexyl ester (Compound DG);

O
HN N~N O NH2 H

Carbamic acid 6-amino-2- f 2-[[2-(4-amino-butylamino)-acetyl]-(5-amino-pentyl)-amino]-acetylamino}-hexyl ester (Compound DH);

~O~NH2 H2 ~N
O
Carbamic acid 6-amino-2-{2-[(2-amino-S-guanidino-pentyloxycarbonyl)-(S-amino-pentyl)-amino]-acetylamino}-hexyl ester (Compound DI);

O
1,5 H2N j~0 N~N O NH2 H
Carbamic acid 6-amino-2-{2-[(2-amino-4-carbamoyl-butoxycarbonyl)-(5-amino-pentyl)-amino]-acetylamino~-hexyl ester (Compound DJ);

~O~NH2 H2 ~N
O
Carbamic acid 6-amino-2-{2-[(7-amino-heptyl)-(2,6-diamino-hexyloxycarbonyl)-amino]-acetylamino}-hexyl ester (Compound DK);

O
j~0 N~ O NH2 H2N ~ N
O H O
Carbamic acid 6-amino-2-{2-[(7-amino-heptyl)-(2,6-diamino-hexyloxycarbonyl)-amino]-acetylamino}-hexyl ester (Compound DL);

O
H N NV \N O NH2 H
Carbamic acid 6-amino-2-{2-[(7-amino-heptyl)-(2,6-diamino-hexanoyl)-amino]-acetylamino}-hexyl ester (Compound DM);

O
H N N~N O NHZ
H
Carbamic acid 6-amino-2-{2-[(7-amino-heptyl)-(2,6-diamino-hexanoyl)-amino]-acetylamino}-hexyl ester (Compound DN);

S
O
HN NV \N O NH2 H
O

Carbamic acid 6-amino-2-(2-{(7-amino-heptyl)-[2-(5-amino-pentylamino)-acetyl]-amino}-acetylamino)-hexyl ester (Compound DO);

O
HN NV \N O NH2 H

Carbamic acid 6-amino-2-(2-{(7-amino-heptyl)-[2-(7-amino-heptylamino)-acetyl]-amino}-acetylamino)-hexyl ester (Compound DP);

HN ~D~NH2 l I Io Carbamic acid 6-amino-2-{2-[[2-(4-amino-butylamino)-acetyl]-(7-amino-heptyl)-amino]-acetylamino}-hexyl ester (Compound DQ);
'NH2 HN~NH J2 NH
r O' /N H2 H2 ~N
O
Carbamic acid 6-amino-2-{2-[(2-amino-5-guanidino-pentyloxycarbonyl)-(7-amino-heptyl)-amino]-acetylamino}-hexyl ester (Compound DR);

O
~O N~N O NH2 H
Carbamic acid 6-amino-2-{2-[(2-amino-4-carbamoyl-butoxycarbonyl)-(7-amino-heptyl)-amino]-acetylamino}-hexyl ester (Compound DS);

HN \ /NH2 NH
H O =
H N O N~N~/O NH2 H

Carbamic acid 6-amino-2-[6-amino-2-(2-amino-5-guanidino-pentyloxycarbonylamino)-hexanoylamino]-hexyl ester (Compound DT);

H O
H2N~O~N~N~O~NH2 ~O H ~O

Carbamic acid 6-amino-2-[6-amino-2-(2-amino-4-carbamoyl-butoxycarbonylamino)-hexanoylamino]-hexyl ester (Compound DU); and pharmaceutically acceptable salts thereof.
5.2.2 THE COMPOUNDS OF FORMULA V
The compounds of formula V and pharmaceutically acceptable salts thereof are ureas and can be obtained via conventional methods (see, for example, K.
Burgess et al., J. Am. Chem. Soc. 119:1556-1564 (1997)).
Urea monomers 10 useful for preparing the compounds of formula V can be obtained according to Fig. 2. The urea monomers are those wherein Rl is -NHz, -NHC(=NH)NHz, or -CHzC(=NH)NHz; and m is an integer ranging from 3 to 7. For example, Na-Fmoc protected amino acids 4 can be reduced to their corresponding amino alcohols 5 by reaction with, for example, N-methyl morpholine and isobutyl chloroformate, followed by treatment with, for example, NaBH4. Deprotection of Fmoc group with, for example, 20% piperidine, followed by reaction with Teoc-ONP and pyridine provides N-Teoc-protected amino alcohols 6. Amino alcohols 6 can be converted to their corresponding azide derivatives 8 via, for example, mesylation with methanesulfonylchloride, which provides mesylate intermediates 7. Mesylate intermediates 7 can then be treated with an azide source to provide azide derivatives 8. The Teoc protecting group can be removed from azide derivatives 8 using, for example, TBAF, to provide deprotected intermediates 9. Deprotected intermediates 9 can then be activated as their nitrophenyloxycarbonyl derivatives using 4-nitrophenylchloroformate to provide urea monomers 10. Urea monomers 10 can be purified using conventional silica gel chromatography.
Preferred compounds of formula V are:
IS HN\ /NH2 HN \ /NHZ
~NH ~NH
O H H O
N~N N~N~N~N NHz H ~O H H
NHz 1- {S-Amino-1-[3-( 1-aminomethyl-4-guanidino-butyl)-ureidomethyl]-pentyl} -3-(S-guanidino-2-ureido-pentyl)-urea (Compound DV);

HN\'NH2 NH
O H H O
HzN~N N~N~N~N NH2 H ~O H H
NHz 1- {S-Amino-1-[3-(S-amino-1-aminomethyl-pentyl)-ureidomethyl]-pentyl} -3-(S-guanidino-2-ureido-pentyl)-urea (Compound DW);
HN \ /NH2 NH
H2NJ''N N N~N~N NH2 H ~ H H
~NH
HN~NH2 1- { 1-[3-(5-Amino-1-aminomethyl-pentyl)-ureidomethyl]-4-guanidino-butyl}-3-(5-guanidino-2-ureido-pentyl)-urea (Compound DX);
HN \ 'NHp ~NH
~u H H
H2N~N N~N~N~N~/NH2 H ICI H H

1- { 5-Amino-1-[3-(2-amino-ethyl)-ureidomethyl]-pentyl} -3-(5-guanidino-2-ureido-pentyl)-urea (Compound DY); and pharmaceutically acceptable salts thereof.
6. THERAPEUTIC USES OF THE COMPOUNDS OF THE
INVENTION
In accordance with the invention, the compounds of the invention can be administered to a patient, preferably a mammal, more preferably a human, suffering from cancer, inflammation, or a viral infection. In one embodiment, "treatment" or "treating"
refers to an amelioration of cancer, inflammation, or a viral infection, or at least one discernible symptom thereof. In another embodiment, "treatment" or "treating"
refers to an amelioration of at least one measurable physical parameter, not necessarily discernible by the patient. In yet another embodiment, "treatment" or "treating" refers to inhibiting the progression of cancer, inflammation, or a viral infection, either physically, e.g., stabilization of a discernible symptom, physiologically, e.g., stabilization of a physical parameter, or both. In yet another embodiment, "treatment" or "treating" refers to delaying the onset of cancer, inflammation, or a viral infection.
In certain embodiments, a compound of the invention is administered to a patient, preferably a mammal, more preferably a human, as a preventative measure against cancer, inflammation, or a viral infection. As used herein, "prevention" or "preventing"
refers to a reduction of the risk of acquiring cancer, inflammation, or a viral infection. In one embodiment, a compound of the invention is administered as a preventative measure to a patient. According to this embodiment, the patient can have a genetic or a non-genetic predisposition to cancer, inflammation, or a viral infection. Accordingly, the compounds of the invention can be used for the treatment of one manifestation of cancer, inflammation, or a viral infection and prevention of another.
6.1 TYPES OF CANCER TREATABLE OR PREVENTABLE
USING THE COMPOUNDS OF THE INVENTION
The compounds of the invention are useful for treating or preventing a variety of cancers, including, but not limited to, Leukemias, including but not limited to acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia, chronic leukemia, chronic myelocytic, (granulocytic) leukemia, chronic lymphocytic leukemia, Polycythemia vera, Lymphomas including but not limited to Hodgkin's disease; non-Hodgkin's disease, Multiple myeloma, Waldenstrom's macroglobulinemia, Heavy chain disease, Solid tumors including but not limited to sarcomas and carcinomas, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, uterine cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, and neuroblastomaretinoblastoma.

6.2 TYPES OF INFLAMMATION TREATABLE OR
PREVENTABLE USING THE COMPOUNDS OF THE
INVENTION
The compounds of the invention are useful for treating or preventing several types of inflammation, including, but not limited to, eczema, inflammatory bowel disease, rheumatoid arthritis, asthma, psoriasis, ischemia/reperfusion injury, ulcerative colitis and acute respiratory distress syndrome.
6.3 TYPES OF VIRAL INFECTIONS TREATABLE OR
PREVENTABLE USING THE COMPOUNDS OF THE
INVENTION
The compounds of the invention are useful for treating or preventing a variety of viral infections, including, but not limited to those caused by infection with hepatitis B, hepatitis C, rotavirus, human immunodeficiency virus type I (HIV-I), human immunodeficiency virus type II (HN-II), human T-cell lymphotropic virus type I
(HTLV-I), human T-cell lymphotropic virus type II (HTLV-II), AIDS, DNA viruses such as hepatitis type B and hepatitis type C virus; parvoviruses, such as adeno-associated virus and cytomegalovirus; papovaviruses such as papilloma virus, polyoma viruses, and SV40;
adenoviruses; herpes viruses such as herpes simplex type I (HSV-I), herpes simplex type II
(HSV-II), and Epstein-Barr virus; poxviruses, such as variola (smallpox) and vaccinia virus;
and RNA viruses, such as human immunodeficiency virus type I (HIV-I), human immunodeficiency virus type II (HN-II), human T-cell lymphotropic virus type I
(HTLV-I), human T-cell lymphotropic virus type II (HTLV-II), influenza virus, measles virus, rabies virus, Sendai virus, picornaviruses such as poliomyelitis virus, coxsackieviruses, rhinoviruses, reoviruses, togaviruses such as rubella virus (German measles) and Semliki forest virus, arboviruses, and hepatitis type A virus.
6.4 THERAPEUTIC/PROPHYLACTIC ADMINISTRATION OF
THE COMPOUNDS OF THE INVENTION
Due to their activity, the compounds of the invention are advantageously useful in veterinary and human medicine. As described above, the compounds of the invention are useful for the treatment or prevention of cancer, inflammation, or a viral infection in a patient.
When administered to a patient, a compound of the invention is preferably administered as component of a composition that optionally comprises a pharmaceutically acceptable vehicle. The present compositions, which comprise a compound of the invention, are preferably administered orally. The compositions of the invention may also be administered by any other convenient route, for example, by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal, and intestinal mucosa, etc.) and may be administered together with another biologically active agent. Administration can be systemic or local. Various delivery systems are known, e.g., encapsulation in liposomes, microparticles, microcapsules, capsules, etc., and can be used to administer the compounds of the invention.
In certain embodiments, the present compositions can comprise one or more compounds of the invention.
Methods of administration include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, oral, sublingual, intranasal, intracerebral, intravaginal, transdermal, rectally, by inhalation, or topically, particularly to the ears, nose, eyes, or skin. The mode of administration is left to the discretion of the practitioner. In most instances, administration will result in the release of a compound of the invention into the bloodstream.
In specific embodiments, it may be desirable to a compound of the invention locally. This may be achieved, for example, and not by way of limitation, by local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers.
In certain embodiments, it may be desirable to introduce a compound of the invention into the central nervous system by any suitable route, including intraventricular, intrathecal and epidural injection. Intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir.
Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent, or via perfusion in a fluorocarbon or synthetic pulmonary surfactant. In certain embodiments, the compounds of the invention can be formulated as a suppository, with traditional binders and vehicles such as triglycerides.
In another embodiment, the compounds of the invention can be delivered in a vesicle, in particular a liposome (see Langer, 1990, Science 249:1527-1533;
Treat et al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989); Lopez-Berestein, ibid., pp. 317-327; see generally ibid.).

In yet another embodiment, the compounds of the invention can be delivered in a controlled release system (see, e.g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138 (1984)). Other controlled-release systems discussed in the review by Larger, 1990, Science 249:1527-1533) may be used. In one embodiment, a pump may be used (see Larger, supra; Sefton, 1987, CRC Crit. Ref. Biomed. Erg.
14:201;
Buchwald et al., 1980, Surgery 88:507 Saudek et al., 1989, N. Engl. J. Med.
321:574). In another embodiment, polymeric materials can be used (see Medical Applications of Controlled Release, Larger and Wise (eds.), CRC Pres., Boca Raton, Florida (1974);
Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, 1983, J. Macromol. Sci.
Rev.
Macromol. Chem. 23:61; see also Levy et al., 1985, Science 228:190; During et al., 1989, Ann. Neurol. 25:351; Howard et al., 1989, J. Neurosurg. 71:105). In yet another embodiment, a controlled-release system can be placed in proximity of a target of a compound of the invention, e.g., a particular RNA, thus requiring only a fraction of the systemic dose.
The present compositions can optionally comprise a suitable amount of a pharmaceutically acceptable vehicle so as to provide the form for proper administration to the patient.
In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S.
Pharmacopeia or other generally recognized pharmacopeia for use in animals, mammals, and more particularly in humans. The term "vehicle" refers to a diluent, adjuvant, excipient, or carrier with which a compound of the invention is administered. Such pharmaceutical vehicles can be liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. The pharmaceutical vehicles can be saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea, and the like. In addition, auxiliary, stabilizing, thickening, lubricating and coloring agents may be used. When administered to a patient, the pharmaceutically acceptable vehicles are preferably sterile. Water is a preferred vehicle when the compound of the invention is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid vehicles, particularly for injectable solutions. Suitable pharmaceutical vehicles also include excipients such as starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The present compositions, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
The present compositions can take the form of solutions, suspensions, emulsion, tablets, pills, pellets, capsules, capsules containing liquids, powders, sustained-release formulations, suppositories, emulsions, aerosols, sprays, suspensions, or any other form suitable for use. In one embodiment, the pharmaceutically acceptable vehicle is a capsule (see e.g., U.S. Patent No. 5,698,155). Other examples of suitable pharmaceutical vehicles are described in Remington's Pharmaceutical Sciences, Alfonso R.
Gennaro ed., Mack Publishing Co. Easton, PA, 19th ed., 1995, pp. 1447 to 1676, incorporated herein by reference.
In a preferred embodiment, the compounds of the invention are formulated in accordance with routine procedures as a pharmaceutical composition adapted for oral administration to human beings. Compositions for oral delivery may be in the form of tablets, lozenges, aqueous or oily suspensions, granules, powders, emulsions, capsules, syrups, or elixirs, for example. Orally administered compositions may contain one or more agents, for example, sweetening agents such as fructose, aspartame or saccharin; flavoring agents such as peppermint, oil of wintergreen, or cherry; coloring agents; and preserving agents, to provide a pharmaceutically palatable preparation. Moreover, where in tablet or pill form, the compositions can be coated to delay disintegration and absorption in the gastrointestinal tract thereby providing a sustained action over an extended period of time.
Selectively permeable membranes surrounding an osmotically active driving compound are also suitable for orally administered compositions. In these later platforms, fluid from the environment surrounding the capsule is imbibed by the driving compound, which swells to displace the agent or agent composition through an aperture. These delivery platforms can provide an essentially zero order delivery profile as opposed to the spiked profiles of immediate release formulations. A time delay material such as glycerol monostearate or glycerol stearate may also be used. Oral compositions can include standard vehicles such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Such vehicles are preferably of pharmaceutical grade.
Typically, compositions for intravenous administration comprise sterile isotonic aqueous buffer. Where necessary, the compositions may also include a solubilizing agent.
In another embodiment, the compounds of the invention can be formulated for intravenous administration. Compositions for intravenous administration may optionally include a local anesthetic such as lignocaine to lessen pain at the site of the injection.
Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent.
Where the compounds of the invention are to be administered by infusion, they can be dispensed, for example, with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the compounds of the invention are administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.
The amount of a compound of the invention that will be effective in the treatment of a particular type of cancer, inflammation, or viral infection disclosed herein will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques. In addition, in vitro or in vivo assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. However, suitable dosage ranges for oral administration are generally about 0.001 milligram to about 200 milligrams of a compound of the invention or a pharmaceutically acceptable salt thereof per kilogram body weight per day. In specific preferred embodiments of the invention, the oral dose is about 0.01 milligram to about 100 milligrams per kilogram body weight per day, more preferably about 0.1 milligram to about 75 milligrams per kilogram body weight per day, more preferably about 0.5 milligram to 5 milligrams per kilogram body weight per day.
The dosage amounts described herein refer to total amounts administered; that is, if more than one compound of the invention is administered, or if a compound of the invention is administered with a therapeutic agent, then the preferred dosages correspond to the total amount administered. Oral compositions preferably contain about 10% to about 95% active ingredient by weight.
Suitable dosage ranges for intravenous (i.v.) administration are about 0.01 milligram to about 100 milligrams per kilogram body weight per day, about 0.1 milligram to about 35 milligrams per kilogram body weight per day, and about 1 milligram to about 10 milligrams per kilogram body weight per day. Suitable dosage ranges for intranasal administration are generally about 0.01 pg/kg body weight per day to about 1 mg/kg body weight per day. Suppositories generally contain about 0.01 milligram to about 50 milligrams of a compound of the invention per kilogram body weight per day and comprise active ingredient in the range of about 0.5% to about 10% by weight.
Recommended dosages for intradermal, intramuscular, intraperitoneal, subcutaneous, epidural, sublingual, intracerebral, intravaginal, transdermal administration or administration by inhalation are in the range of about 0.001 milligram to about 200 milligrams per kilogram of body weight per day. Suitable doses for topical administration are in the range of about 0.001 milligram to about 1 milligram, depending on the area of administration. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems. Such animal models and systems are well known in the art.
The invention also provides pharmaceutical packs or kits comprising one or more vessels containing a compound of the invention. Optionally associated with such containers) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.
In a certain embodiment, the kit contains more than one compound of the invention. In another embodiment, the kit comprises a therapeutic agent and a compound of the invention.
The compounds of the invention are preferably assayed in vitro and in vivo, for the desired therapeutic or prophylactic activity, prior to use in humans.
For example, in vitro assays can be used to determine whether it is preferable to administer a compound of the invention alone or in combination with another compound of the invention and/or a therapeutic agent. Animal model systems can be used to demonstrate safety and efficacy.
Other methods will be known to the skilled artisan and are within the scope of the invention.
6.5 COMBINATION THERAPY
In certain embodiments of the present invention, a compound of the invention can be used in combination therapy with at least one other therapeutic agent.
The compound of the invention and the therapeutic agent can act additively or, more preferably, synergistically. In a preferred embodiment, a composition comprising a compound of the invention is administered concurrently with the administration of another therapeutic agent, which can be part of the same composition as or in a different composition from that comprising the compound of the invention. In another embodiment, a composition comprising a compound of the invention is administered prior or subsequent to administration of another therapeutic agent. As many of the disorders for which the compounds of the invention are useful in treating are chronic, in one embodiment combination therapy involves alternating between administering a composition comprising a compound of the invention and a composition comprising another therapeutic agent, e.g., to minimize the toxicity associated with a particular drug. The duration of administration of the compound of the invention or therapeutic agent can be, e.g., one month, three months, six months, a year, or for more extended periods. In certain embodiments, when a compound of the invention is administered concurrently with another therapeutic agent that potentially produces adverse side effects including, but not limited to, toxicity, the therapeutic agent can advantageously be administered at a dose that falls below the threshold at which the adverse side is elicited.
The therapeutic agent can be an anti-cancer agent. Useful anti-cancer agents include, but are not limited to, methotrexate, taxol, mercaptopurine, thioguanine, hydroxyurea, cytarabine, cyclophosphamide, ifosfamide, nitrosoureas, cisplatin, carboplatin, mitomycin, dacarbazine, procarbizine, etoposides, campathecins, bleomycin, doxorubicin, idarubicin, daunorubicin, dactinomycin, plicamycin, mitoxantrone, asparaginase, vinblastine, vincristine, vinorelbine, paclitaxel, and docetaxel, y-radiation, alkylating agents including nitrogen mustard such as cyclophosphamide, Ifosfamide, trofosfamide, Chlorambucil, nitrosoureas such as carmustine (BCNU), and Lomustine (CCNU), alkylsulphonates such as 1 S busulfan, and Treosulfan, triazenes such as Dacarbazine, platinum containing compounds such as Cisplatin and carboplatin, plant alkaloids including vinca alkaloids, vincristine, Vinblastine, Vindesine, and Vinorelbine, taxoids inclduding paclitaxel, and Docetaxol, DNA
topoisomerase inhibitors including Epipodophyllins such as etoposide, Teniposide, Topotecan, 9-aminocamptothecin, campto irinotecan, and crisnatol, mytomycins such as mytomycin C, and Mytomycin C, anti-metabolites, including anti-folates such as DHFR
inhibitors, methotrexate and Trimetrexate, IMP dehydrogenase inhibitors including mycophenolic acid, Tiazofurin, Ribavirin, EICAR, Ribonuclotide reductase Inhibitors such as hydroxyurea, deferoxamine, pyrimidine analogs including uracil analogs 5-Fluorouracil, Floxuridine, Doxifluridine, and Ratitrexed, cytosine analogs such as cytarabine (ara C), cytosine arabinoside, and fludarabine, purine analogs such as mercaptopurine, thioguanine, hormonal therapies including receptor antagonists, the anti-estrogens Tamoxifen, Raloxifene and megestrol, LHRH agonists such as goscrclin, and Leuprolide acetate, anti-androgens such as flutamide, and bicalutamide, retinoids/deltoids, Vitamin D3 analogs including EB
1089, CB 1093, and KH 1060, photodyamic therapies including vertoporfin (BPD-MA), Phthalocyanine, photosensitizer Pc4, Demethoxy-hypocrellin A, (2BA-2-DMHA), cytokines including Interferon-a, Interferon-'y, tumor necrosis factor, as well as other compounds having anti-tumor activity including Isoprenylation inhibitors such as Lovastatin, Dopaminergic neurotoxins such as 1-methyl-4-phenylpyridinium ion, Cell cycle inhibitors such as staurosporine, Actinomycins such as Actinomycin D and Dactinomycin, Bleomycins such as bleomycin A2, Bleomycin B2, and Peplomycin, anthracyclines such as daunorubicin, Doxorubicin (adriamycin), Idarubicin, Epirubicin, Pirarubicin, Zorubicin, and Mitoxantrone, MDR inhibitors including verapamil, and Caz+ATPase inhibitors such as thapsigargin.
The therapeutic agent can be an anti-inflammatory agent. Useful anti-inflammatory agents include, but are not limited to, non-steroidal anti-inflammatory drugs such as salicylic acid, acetylsalicylic acid, methyl salicylate, diflunisal, salsalate, olsalazine, sulfasalazine, acetaminophen, indomethacin, sulindac, etodolac, mefenamic acid, meclofenamate sodium, tolmetin, ketorolac, dichlofenac, ibuprofen, naproxen, naproxen sodium, fenoprofen, ketoprofen, flurbinprofen, oxaprozin, piroxicam, meloxicam, ampiroxicam, droxicam, pivoxicam, tenoxicam, nabumetome, phenylbutazone, oxyphenbutazone, antipyrine, aminopyrine, apazone and nimesulide; leukotriene antagonists including, but not limited to, zileuton, aurothioglucose, gold sodium thiomalate and auranofin; and other anti-inflammatory agents including, but not limited to, colchicine, allopurinol, probenecid, sulfinpyrazone and benzbromarone.
The therapeutic agent can be an antiviral agent. Useful antiviral agents include, but are not limited to, nucleoside analogs, such as zidovudine, acyclovir, gangcyclovir, vidarabine, idoxuridine, trifluridine, and ribavirin, as well as foscarnet, amantadine, rimantadine, saquinavir, indinavir, ritonavir, and the alpha-interferons.
7. EXAMPLES: CHEMICAL SYNTHESIS
7.1 SYNTHESIS OF CARBAMATE MONOMERS 3 DERIVED
FROM L-ARG, D-ARG, L-LYS, AND D-LYS
10 mmol of each of N"-Fmoc-protected L-Arg, D-Arg, L-Lys, and D-Lys were reduced to its corresponding amino alcohols by reaction with N-methyl morpholine (10 Col) and isobutyl chloroformate (10 mmol) in 1,2-dimethoxyethane (10 mL) at -15 °C, followed by treatment with NaBH4 (30 mmol) in water (10 mL). The resulting product was dissolved in pyridine (10 mmol) and dichloromethane (25 mL) and treated with 4-nitrochlorophenylchloroformate at 0°C for 3 h. Purification using silica gel chromatography provided carbamate monomers 3 derived from each of L-Arg, D-Arg, L-Lys, and D-Lys in approximately 85% yield.

7.2. SYNTHESIS OF UREA MONOMERS 10 DERIVED FROM
L-ARG, L-LYS, L-GLU, L-GLN, GLY, AND L-TYR
mmol of each of L-Arg, L-Lys, L-Glu, L-Gln, Gly, and L-Tyr were reduced to its corresponding amino alcohol by the reaction with N-methyl morpholine (10 mmol) and 5 isobutyl chloroformate (10 mmol) in 1,2-dimethoxyethane (IOmL) at -15 °C, followed by treatment with NaBH4 (30 mmol) in water (10 mL). Deprotection of the resulting product's Fmoc group using 20% piperidine in dichloromethane (50 mL) at room temperature for 1 h, followed by reaction with 2-(trimethylsilyl)ethyl-4-nitrophenyl carbonate (1.
equiv.) and pyridine (1 equiv.) in dichloromethane (25 mL) provided a Teoc-protected amino alcohol.
10 The amino alcohol was converted to its corresponding azide through mesylation with methanesulfonylchloride (1.2 equiv.) and pyridine (1.2 equiv.) in dichloromethane (25 mL) at 0°C. The resulting product was treated with NaN3 (10 equiv.) in dimethylformamide (25 mL) at 60°C for 6 h. The product's Teoc protecting group was removed with 1.0 M
tetrabutylammonium fluoride in THF (20 mL). The resulting free amine was activated as its nitrophenyloxycarbonyl derivative with 4-nitrophenylchloroformate (1.2 equiv.) in presence of pyridine (1.2 equiv.) in dichloromethane at 0°C. Purification using silica gel chromatography provided urea monomers 10 derived from each of L-Arg, L-Lys, L-Glu, L-Gln, Gly, and L-Try in approximately 35% yield.
7.3 SYNTHESIS OF COMPOUND DW
Compound DW was synthesized according to Fig. 4 and Fig. 5. In particular, 54 mg of rink amide HMBA resin (11) (Calbiochem-Novabiochem Corp., La Jolla, CA), was washed with methylene chloride (3 mL x 5min x 2), and suspended in 20% DMF in methylene chloride (2 mL). To the suspended resin was added ArgU (54 mg) in DIPEA (60 uL), and the resulting suspension was allowed to stir overnight at room temperature to provide resin 12.
Resin 12 was washed with DMF (3 mL x 5 min x 3) and with methylene chloride (3 mL x 5 min x 2), suspended in THF (1 mL), and stirred for 20 minutes at room temperature, and to the suspension was added TEA (120 ~L), thiophenol (62 uL), and tin(II) chloride (30 mg). The resulting reaction mixture was allowed to stir for 6 h at room temperature, providing resin 13.
Resin 13 was washed with DMF (3 mL x 5 mm x 3) and methylene chloride (3 mL x 5 min x 2). Two successive iterations of LysU (40 mg x 2) coupling were performed, affording resins 14 and 15, respectively, (Fig. 4 and Fig. 5) as described above for ~gU_ The resin 15 was deprotected and cleaved from resin using 2% TIPS and 2%
water in TFA (2 mL) for 6 h at room temperature. The reaction suspension was filtrated off, and the filtrate was evaporated under reduced pressure to provide a residue. The residue was dissolved in TFA (100 uL), and a crude product was precipitated by addition of ethyl ether (10 mL). HPLC purification using gradient elution (0.1% TFA/H20; 0.1%
TFA/CH3CN, 100; 0 to 0; 100) of the crude product afforded 3 mg of Compound DW as a white solid trimer: FAB/MS m/z 538 (M+Na)+.
7.4 SYNTHESIS OF COMPOUND AU
Compound AU was synthesized according to Fig. 3. In particular, 54 mg of rink amide MBHA resin, 4-(2',4'-dimethoxyphenyl-Fmoc-aminomethyl)-phenoxyacetamido-norleucyl-methylbenzhydrylamine 11 (Calbiochem- Novabiochem Corp., La Jolla, CA), was washed with methylene chloride (3 mL x Smin x 2) and suspended in 20% DMF in methylene chloride (2 mL). To the suspension was added HOBT (240 ~L of 1M in NMP and (D)-LysCar monomer (0.12 mmol). The resulting mixture was allowed to stir for 20 minutes at room temperature, and then 1,3-diisopropyldicarboimide ("DIPDCI") (0.06mmol) was added. The resulting mixture was allowed to stir overnight at room temperature. The solvent was drained and the reaction resin was washed with DMF (10 mL x 5 min x 3) and methylene chloride (10 mL x 5 min x 2) and treated with 5% piperidine/DMF (2 mL) for 10 minutes at room temperature. The solvent was drained, and the resin was retreated with 5%
piperidine/DMF (2 mL) for another 20 min at room temperature and washed extensively with DMF, methanol, and methylene chloride to provide resin 16.
Resin 16 was resuspended in 20% DMF in methylene chloride (2 mL), and then to the suspension was added HOBT (300 uL of 1M in NMP) and N-E-(tert-butoxycarbonyl)-L-lysine (0.3 mmol). The resulting mixture was allowed to stir for 20 minutes at room temperature, and then DIPDCI (0.06 mmol) was added. The resulting mixture was allowed to stir overnight at room temperature. The solvents were drained, and the resin was washed with DMF (10 mL x S mm x 3) and methylene chloride (10 mL
x 5 min x 2) and treated with 2 mL of 5% piperidinelDMF for 10 min at room temperature. The solvent was drained, and the resin was retreated with 5% piperidine/DMF (2 mL) for another 20 min at room temperature and washed extensively with DMF, methanol, and methylene chloride to provide resin 17.
Resin 17 was resuspended in 5% DMF/methylene chloride (2 mL) and allowed to stir for 20 min at room temperature. Bromoacetic acid (140 mg) and HOBT (1 mL of 1M in NMP) was added to the resulting suspension, which was allowed to stir for 20 min at room temperature. 1,3-Diisopropyldicarboimide (0.06 mmol) was added to the resulting suspension, which was allowed to stir overnight at room temperature.
The solvent was drained, and the resulting resin was washed with DMF, methanol, and methylene chloride. The resin was resuspended in DMF (1 mL), to which was added N-Boc-diaminobutane (1 mL, 1M solution in DMF). The resulting mixture was allowed to stir overnight at room temperature. The solvents were drained, and the resulting resin was washed with DMF, methanol, and methylene chloride to provide resin 18.
Resin 18 was treated with methylene chloride (1 ml), thioanisole (0.2 ml), ethanedithiol (0.05 u1), and TFA (2 ml) for 6 hours at room temperature. After stirnng, the resin beads were filtrated off, and the filtrate was dried under reduced pressure overnight to provide a crude product. HPLC purification using gradient elution (0.1 TFA/HZO; 0.1 % TFA/CH3CN, 100; 0 to 0; 100) of the crude product provided 4 mg of Compound AU as a white solid: ESI/MS m/z 431 (M+).
7.5 SYNTHESIS OF COMPOUNDS AA-AT, AV-DV, DX, AND DY
Compounds AA-AT, AV-DV, DX, and DY were synthesized according to the methods used for synthesizing Compounds AU and DW, described above, using appropriate monomers.
8. EXAMPLE: BINDING TO HIV TAR RNA
Binding of compounds of formula I and V to TAR RNA was measured by evaluating their inhibition of TAR-TAT complex formation in the presence of increasing levels of the compound to be tested. The compounds of formula I were tested in an in vitro assay; the compounds of formula V were tested in an in vivo assay.
The TAR RNA used corresponds to the minimal sequence required for TAT
responsiveness in vivo. This 29-residue oligonucleotide has the sequence:
5'-GGCAGAUCUGAGCCUGGGAGCUCUCUGCC-3' (SEQ LD NO.: 1). TAR RNA was prepared by in vitro transcription. A "top strand" single-stranded DNA
oligomer having the sequence 5'-TAATACGACTCACTATAG-3' (SEQ ID NO.: 2) was annealed to a "bottom strand" single-stranded DNA template having the following sequence:
3'-ATTATGCTAAGTGATATCCCGTCTAGACTCGGACCCTCGAGAGACGG-5' (SEQ
ID NO.: 3), thereby generating a double-stranded region corresponding to a promoter sequence recognized by T7 RNA polymerase. Transcription was carried out in transcription buffer (40 mM Tris-HCI, pH 8.1, 1mM spermidine, 0.01% Triton~X-100, 5 mM
dithiothreitol, 4 mM each of ATP, GTP, CTP, and UTP at 37 ° C for 4 to 5 hours. Reactions were performed in a volume of 0.02 ml containing 8 pmole of template (top strand annealed to bottom strand) and 40 to 60 units of T7 RNA polymerase. Transcription was terminated by adding an equal volume of loading buffer (9M urea, lmmol EDTA, O.1M
bromophenol blue in 1 XTBE buffer; TBE is 45mmo1 trisborate at pH 8). Product RNA was purified by electrophoresis through a denaturing 20% polyacrylamide gel containing 8M
urea. RNA
was extracted from the gel, precipitated, dissolved in dithylpyrocarbonate-treated water, and stored at -20° C until used.
In vitro assay conditions: Compounds AA-DU were synthesized on TentaGel S-NHZ (4.6 mmole). All Fmoc-amino acids were purchased from Bachem (Torrance, CA). 1-hydroxybenzotriazole (HOBT) and diisopropylcarbodiimide (DIPCDI) were obtained from Aldrich Chemical Co., Milwalkee, WI. Piperidine and trifluoroacetic acid were purchased from Applied Biosystems Division, Perkin-Elmer. Compounds AA-DU were synthesized manually according to standard solid-phase peptide synthesis protocols.
Coupling efficiencies of residues at each step were monitored by Kaiser test.
Deprotection of trimer peptides was carned out in 10% water in trifluoroacetic acid (1 mL) for 16 hours at room temperature. After filtration of solvents, the resin was washed with water (1 mL x 4), DMF
(1 mL x 4), dichloromethane (1 mL x 4), and dried under reduced pressure. The compounds attached to the resin (10 beads) were placed in an Eppendorf tube and washed with TK buffer (200 mL x 3). The beads were suspended in TK buffer (300 mL) and incubated with TAR
RNA (1.95 mM) overnight at 4°C. The suspension was centrifuged and the supernatant containing unbound RNA was transferred to a cuvette for OD26o measurements.
The UV
absorbance was measured by a Shimadzu UV-1601 spectrometer. Equilibrium concentrations of RNA were determined from these measurements . Given that the initial concentrations of ligand and RNA are known, and assuming simple bimolecular receptor/substrate binding, dissociation constant (KD) was calculated from straightforward equations.
TAT peptide has the amino acid sequence: GRKKRRQRRR (SEQ ID NO.: 4) which corresponds to amino acids 48-57 of the intact protein.
In vivo assay conditions: HL3T1 cells, a HeLa cell line derivative containing an integrated HIV-1 LTR promoter and CAT reporter gene, were used. Cells were grown in 2 mL of Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal calf serum in 60mm dishes at 37°C in 5% CO in a tissue culture incubator.
Cells were refreshed by 2 mL DMEM before transfection. Transfection was started by dropwise addition of 250 pL 2 x HeBS (Hepes-buffered saline) and then keeping at room temperature for 10 minutes.
Approximately 10 pg of plasmids (pSV2Tat and pAL) and increasing amounts of the Compounds DV, DW, DX or DY were transfected in the presence of CaCl2 (final concentration 125 mM) and the cells were incubated for 4 hour at 37°C
in a tissue culture incubator. The medium was then discarded and the cells were subjected to glycerol (1.5 mL
of 1 S%) shock for 45 seconds. Finally the cells were washed twice with PBS (5 mL) and were grown in 3 mL DMEM. The cells were harvested after 48 hour post-transfection with changing with fresh DMEM at 24 hours and lysed in reporter lysis buffer (Promega).
Aliquots were used for CAT and luciferase assays. Both activities were normalized to protein concentration determined by using a modified Bradford assay (Bio-Rad).
The binding data obtained, which demonstrate that the compounds of the invention inhibit TAT-peptide TAR-RNA interaction, are summarized in Table I:
TABLE I: BINDING CONSTANTS
Com ound Kd (nM) ~ 491 Com ound Kd nM) AZ' 403 Bp 2191 Com ound Kd nM) Com ound Kd nM

Dp 774 Com ound Ki nM

DW SO

The present invention is not to be limited in scope by the specific embodiments disclosed in the examples which are intended as illustrations of a few aspects of the invention and any embodiments which are functionally equivalent are within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art and are intended to fall within the appended claims.
A number of references have been cited, the entire disclosures of which are incorporated herein by reference.

SEQUENCE LISTING
<110> UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
<120> CARBAMATES AND UREAS, COMPOSITIONS THEREOF, AND METHODS
FOR THEIR USE FOR TREATING OR PREVENTING CANCER, INFLAMMATION, OR A VIRAL INFECTION
<130> 10589-003-228 <150> 60/157,646 <151> 1999-10-04 <160> 4 <170> FastSEQ for Windows Version 3.0 <210> 1 <211> 29 <212> RNA
<213> HIV-1 <400> 1 ggcagaucug agccugggag cucucugcc 29 <210> 2 <211> 18 <212> DNA
<213> Artificial Sequence <220>
<223> T7 promoter <400> 2 taatacgact cactatag 18 <210> 3 <211> 47 <212> DNA
<213> Artificial Sequence <220>
<223> Template strand <400> 3 ggcagagagc tcccaggctc agatctgccc tatagtgaat cgtatta 47 <210> 4 <211> 10 <212> PRT
<213> HIV-1 <400> 4 Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg

Claims (28)

What is claimed is:
1. A compound of formula I:

H~Y~Y~Y-NH2 I

and pharmaceutically acceptable salts thereof, wherein each Y is independently a radical having the structure of II, III, or IV:

each R1 is independently selected from the group consisting of-NH2, -NHC(=NH)NH2, and -CH2C(=NH)NH2;
each m is independently an integer ranging from 3 to 7;
each * is an (R) or (S) chiral center; and with the proviso that at least one Y is a radical having the structure of IV.
2. The compound of claim 1, wherein at least two Y are independently a radical having the structure of IV.
3. The compound of claim 1, wherein each Y is independently a radical having the structure of IV.
4. The compound of claim 1, selected from the group consisting of:

Carbamic acid 6-amino-2-[6-amino-2-(2,6-diamino-hexyloxycarbonylamino)-hexyloxycarbonylamino]-hexyl ester (Compound AA);

Carbamic acid 6-amino-2-[6-amino-2-(2,6-diamino-hexyloxycarbonylamino)-hexyloxycarbonylamino]-hexyl ester (Compound AB);

Carbamic acid 6-amino-2-[6-amino-2-(2,6-diamino-hexanoylamino)-hexyloxycarbonylamino]-hexyl ester (Compound AC);

Carbamic acid 6-amino-2-[6-amino-2-(2,6-diamino-hexanoylamino)-hexyloxycarbonylamino]-hexyl ester (Compound AD);

Carbamic acid 6-amino-2-{6-amino-2-[2-(5-amino-pentylamino)-acetylamino]-hexyloxycarbonylamino}-hexyl ester (Compound AE);

Carbamic acid 6-amino-2-{6-amino-2-[2-(7-amino-heptylamino)-acetylamino]-hexyloxycarbonylamino}-hexyl ester (Compound AF);

Carbamic acid 6-amino-2-{6-amino-2-[2-(4-amino-butylamino)-acetylamino]-hexyloxycarbonylamino}-hexyl ester (Compound AG);

Carbamic acid 6-amino-2-[6-amino-2-(2-amino-5-guanidino-pentyloxycarbonylamino)-hexyloxycarbonylamino]-hexyl ester (Compound AH);

Carbamic acid 6-amino-2-[6-amino-2-(2-amino-4-carbamoyl-butoxycarbonylamino)-hexyloxycarbonylamino]-hexyl ester (Compound AI);

Carbamic acid 6-amino-2-[6-amino-2-(2,6-diamino-hexyloxycarbonylamino)-hexyloxycarbonylamino]-hexyl ester (Compound AJ);

Carbamic acid 6-amino-2-[6-amino-2-(2,6-diamino-hexyloxycarbonylamino)-hexyloxycarbonylamino]-hexyl ester (Compound AK);

Carbamic acid 6-amino-2-[6-amino-2-(2,6-diamino-hexanoylamino)-hexyloxycarbonylamino]-hexyl ester (Compound AL);

Carbamic acid 6-amino-2-[6-amino-2-(2,6-diamino-hexanoylamino)-hexyloxycarbonylamino]-hexyl ester (Compound AM);

Carbamic acid 6-amino-2-{6-amino-2-[2-(5-amino-pentylamino)-acetylamino]-hexyloxycarbonylamino}-hexyl ester (Compound AN);0 Carbamic acid 6-amino-2-{6-amino-2-[2-(7-amino-heptylamino)-acetylamino]-hexyloxycarbonylamino]-hexyl ester (Compound AO);

Carbamic acid 6-amino-2-{6-amino-2-[2-(4-amino-butylamino)-acetylamino]-hexyloxycarbonylamino}-hexyl ester (Compound AP);

Carbamic acid 6-amino-2-[6-amino-2-(2-amino-5-guanidino-pentyloxycarbonylamino)-hexyloxycarbonylamino]-hexyl ester (Compound AQ);

Carbamic acid 6-amino-2-[6-amino-2-(2-amino-4-carbamoyl-butoxycarbonylamino)-hexyloxycarbonylamino]-hexyl ester (Compound AR);

Carbamic acid 6-amino-2-{2-[(4-amino-butyl)-(2,6-diamino-hexyloxycarbonyl)-amino]-acetylamino}-hexyl ester (Compound AS);

Carbamic acid 6-amino-2-{2-[(4-amino-butyl)-(2,6-diamino-hexyloxycarbonyl)-amino]-acetylamino}-hexyl ester (Compound AT);

Carbamic acid 6-amino-2-{2-[(4-amino-butyl)-(2,6-diamino-hexanoyl)-amino]-acetylamino}-hexyl ester (Compound AU);

Carbamic acid 6-amino-2-{2-[(4-amino-butyl)-(2,6-diamino-hexanoyl)-amino]-acetylamino}-hexyl ester (Compound AV);

Carbamic acid 6-amino-2-(2-{(4-amino-butyl)-[2-(4-amino-butylamino)-acetyl]-amino}-acetylamino)-hexyl ester (Compound AW);

Carbamic acid 6-amino-2-(2-{(4-amino-butyl)-[2-(7-amino-heptylamino)-acetyl]-amino}-acetylamino)-hexyl ester (Compound AX);

Carbamic acid 6-amino-2-(2-{(4-amino-butyl)-[2-(4-amino-butylamino)-acetyl]-amino}-acetylamino)-hexyl ester (Compound AY);

Carbamic acid 6-amino-2-{2-[(4-amino-butyl)-(2-amino-5-guanidine-pentyloxycarbonyl)-amino]-acetylamino}-hexyl ester (Compound AZ);

Carbamic acid 6-amino-2-{2-[(4-amino-butyl)-(2-amino-4-carbamoyl-butoxycarbonyl)-amino]-acetylamino}-hexyl ester (Compound BA);

Carbamic acid 6-amino-2-{2-[(5-amino-pentyl)-(2,6-diamino-hexyloxycarbonyl)-amino]-acetylamino}-hexyl ester (Compound BB);

Carbamic acid 6-amino-2-{2-[(5-amino-pentyl)-(2,6-diamino-hexyloxycarbonyl)-amino]-acetylamino}-hexyl ester (Compound BC);

Carbamic acid 6-amino-2-{2-[(5-amino-pentyl)-(2,6-diamino-hexanoyl)-amino]-acetylamino}-hexyl ester (Compound BD);

Carbamic acid 6-amino-2-{2-[(5-amino-pentyl)-(2,6-diamino-hexanoyl)-amino]-acetylamino}-hexyl ester (Compound BE);
Carbamic acid 6-amino-2-(2-{(S-amino-pentyl)-[2-(5-amino-pentylamino)-acetyl]-amino}-acetylamino)-hexyl ester (Compound BF);
Carbamic acid 6-amino-2-{2-[[2-(7-amino-heptylamino)-acetyl]-(5-amino-pentyl)-amino]-acetylamino}-hexyl ester (Compound BG);

Carbamic acid 6-amino-2-{2-[[2-(4-amino-butylamino)-acetyl]-(5-amino-pentyl)-amino]-acetylamino}-hexyl ester (Compound BH);
Carbamic acid 6-amino-2-{2-[(2-amino-5-guanidino-pentyloxycarbonyl)-(5-amino-pentyl)-amino]-acetylamino}-hexyl ester (Compound BI);
Carbamic acid 6-amino-2-{2-[(2-amino-4-carbamoyl-butoxycarbonyl)-(5-amino-pentyl)-amino]-acetylamino}-hexyl ester (Compound BJ);

Carbamic acid 6-amino-2-{2-[(7-amino-heptyl)-(2,6-diamino-hexyloxycarbonyl)-amino]-acetylamino}-hexyl ester (Compound BK);
Carbamic acid 6-amino-2-{2-[(7-amino-heptyl)-(2,6-diamino-hexyloxycarbonyl)-amino]-acetylamino}-hexyl ester (Compound BL);
Carbamic acid 6-amino-2-{2-[(7-amino-heptyl)-(2,6-diamino-hexanoyl)-amino]-acetylamino}-hexyl ester (Compound BM);

Carbamic acid 6-amino-2-{2-[(7-amino-heptyl)-(2,6-diamino-hexanoyl)-amino]-acetylamino}-hexyl ester (Compound BN);
Carbamic acid 6-amino-2-(2-{(7-amino-heptyl)-[2-(5-amino-pentylamino)-acetyl]-amino}-acetylamino)-hexyl ester (Compound BO);

Carbamic acid 6-amino-2-(2-{(7-amino-heptyl)-[2-(7-amino-heptylamino)-acetyl]-amino}-acetylamino)-hexyl ester (Compound BP);
Carbamic acid 6-amino-2-{2-[[2-(4-amino-butylamino)-acetyl]-(7-amino-heptyl)-amino]-acetylamino}-hexyl ester (Compound BQ);

Carbamic acid 6-amino-2-{2-[(2-amino-5-guanidino-pentyloxycarbonyl)-(7-amino-heptyl)-amino]-acetylamino}-hexyl ester (Compound BR);
Carbamic acid 6-amino-2-{2-[(2-amino-4-carbamoyl-butoxycarbonyl)-(7-amino-heptyl)-amino]-acetylamino}-hexyl ester (Compound BS);
Carbamic acid 6-amino-2-[6-amino-2-(2,6-diamino-hexyloxycarbonylamino)-hexanoylamino]-hexyl ester (Compound BT);

Carbamic acid 6-amino-2-[6-amino-2-(2,6-diamino-hexyloxycarbonylamino)-hexanoylamino]-hexyl ester (Compound BU);
Carbamic acid 6-amino-2-[6-amino-2-(2,6-diamino-hexanoylamino)-hexanoylamino]-hexyl ester (Compound BV);
Carbamic acid 6-amino-2-[6-amino-2-(2,6-diamino-hexanoylamino)-hexanoylamino]-hexyl ester (Compound BW);

Carbamic acid 6-amino-2-{6-amino-2-[2-(5-amino-pentylamino)-acetylamino]-hexanoylamino}-hexyl ester (Compound BX);
Carbamic acid 6-amino-2-{6-amino-2-[2-(7-amino-heptylamino)-acetylamino]-hexanoylamino}-hexyl ester (Compound BY);

Carbamic acid 6-amino-2-{6-amino-2-[2-(4-amino-butylamino)-acetylamino]-hexanoylamino}-hexyl ester (Compound BZ);
Carbamic acid 6-amino-2-[6-amino-2-(2,6-diamino-hexyloxycarbonylamino)-hexyloxycarbonylamino]-hexyl ester (Compound CA);
Carbamic acid 6-amino-2-[6-amino-2-(2,6-diamino-hexyloxycarbonylamino)-hexyloxycarbonylamino]-hexyl ester (Compound CB);

Carbamic acid 6-amino-2-[6-amino-2-(2,6-diamino-hexanoylamino)-hexyloxycarbonylamino]-hexyl ester (Compound CC);

Carbamic acid 6-amino-2-[6-amino-2-(2,6-diamino-hexanoylamino)-hexyloxycarbonylamino]-hexyl ester (Compound CD);

Carbamic acid 6-amino-2-{6-amino-2-[2-(5-amino-pentylamino)-acetylamino]-hexyloxycarbonylamino}-hexyl ester (Compound CE);

Carbamic acid 6-amino-2-{6-amino-2-[2-(7-amino-heptylamino)-acetylamino]-hexyloxycarbonylamino{-hexyl ester (Compound CF);

Carbamic acid 6-amino-2-{6-amino-2-[2-(4-amino-butylamino)-acetylamino]-hexyloxycarbonylamino}-hexyl ester (Compound CG);

Carbamic acid 6-amino-2-[6-amino-2-(2-amino-5-guanidino-pentyloxycarbonylamino)-hexyloxycarbonylamino]-hexyl ester (Compound CH);

Carbamic acid 6-amino-2-[6-amino-2-(2-amino-5-guanidino-pentyloxycarbonylamino)-hexyloxycarbonylamino]-hexyl ester (Compound CI);

Carbamic acid 6-amino-2-[6-amino-2-(2,6-diamino-hexyloxycarbonylamino)-hexyloxycarbonylamino]-hexyl ester (Compound CJ);

Carbamic acid 6-amino-2-[6-amino-2-(2,6-diamino-hexyloxycarbonylamino)-hexyloxycarbonylamino]-hexyl ester (Compound CK);

acid 6-amino-2-[6-amino-2-(2,6-diamino-hexanoylamino)-hexyloxy Carbamic carbonylamino]-hexyl ester (Compound CL);

Carbamic acid 6-amino-2-[6-amino-2-(2,6-diamino-hexanoylamino)-hexyloxycarbonylamino]-hexyl ester (Compound CM);

Carbamic acid 6-amino-2-{6-amino-2-[2-(5-amino-pentylamino)-acetylamino]-hexyloxycarbonylamino}-hexyl ester (Compound CN);

Carbamic acid 6-amino-2-{6-amino-2-[2-(7-amino-heptylamino)-acetylamino]-hexyloxycarbonylamino}-hexyl ester (Compound CO);

Carbamic acid 6-amino-2-{6-amino-2-[2-(4-amino-butylamino)-acetylamino]-hexyloxycarbonylamino}-hexyl ester (Compound CP);

Carbamic acid 6-amino-2-[6-amino-2-(2-amino-5-guanidino-pentyloxycarbonylamino)-hexyloxycarbonylamino]-hexyl ester (Compound CQ);

Carbamic acid 6-amino-2-[6-amino-2-(2-amino-4-carbamoyl-butoxycarbonylamino)-hexyloxycarbonylamino]-hexyl ester (Compound CR);

Carbamic acid 6-amino-2-{2-[(4-amino-butyl)-(2,6-diamino-hexyloxycarbonyl)-amino]-acetylamino{-hexyl ester (Compound CS);

Carbamic acid 6-amino-2-{2-[(4-amino-butyl)-(2,6-diamino-hexyloxycarbonyl)-amino]-acetylamino}-hexyl ester (Compound CT);

Carbamic acid 6-amino-2-{2-[(4-amino-butyl)-(2,6-diamino-hexanoyl)-amino]-acetylamino}-hexyl ester (Compound CU);

Carbamic acid 6-amino-2-{2-[(4-amino-butyl)-(2,6-diamino-hexanoyl)-amino]-acetylamino}-hexyl ester (Compound CV);

Carbamic acid 6-amino-2-(2-{(4-amino-butyl)-[2-(5-amino-pentylamino)-acetyl]-amino}-acetylamino)-hexyl ester (Compound CW);

Carbamic acid 6-amino-2-(2-{(4-amino-butyl)-[2-(7-amino-heptylamino)-acetyl]-amino}-acetylamino)-hexyl ester (Compound CX);

Carbamic acid 6-amino-2-(2-{(4-amino-butyl)-[2-(4-amino-butylamino)-acetyl]-amino}-acetylamino)-hexyl ester (Compound CY);

Carbamic acid 6-amino-2-{2-[(4-amino-butyl)-(2-amino-5-guanidino-pentyloxycarbonyl)-amino]-acetylamino}-hexyl ester (Compound CZ);

Carbamic acid 6-amino-2-{2-[(4-amino-butyl)-(2-amino-4-carbamoyl-butoxycarbonyl)-amino]-acetylamino}-hexyl ester (Compound DA);

Carbamic acid 6-amino-2-{2-[(5-amino-pentyl)-(2,6-diamino-hexyloxycarbonyl)-amino]-acetylamino}-hexyl ester (Compound DB);

Carbamic acid 6-amino-2- f 2-[(5-amino-pentyl)-(2,6-diamino-hexyloxycarbonyl)-amino]-acetylamino}-hexyl ester (Compound DC);

Carbamic acid 6-amino-2-{2-[(5-amino-pentyl)-(2,6-diamino-hexanoyl)-amino]-acetylamino}-hexyl ester (Compound DD);

Carbamic acid 6-amino-2-[2-[(5-amino-pentyl)-(2,6-diamino-hexanoyl)-amino]-acetylamino}-hexyl ester (Compound DE);

Carbamic acid 6-amino-2-(2-{(5-amino-pentyl)-[2-(5-amino-pentylamino)-acetyl]-amino]-acetylamino)-hexyl ester (Compound DF);

Carbamic acid 6-amino-2-{2-[[2-(7-amino-heptylamino)-acetyl]-(5-amino-pentyl)-amino]-acetylamino}-hexyl ester (Compound DG);

Carbamic acid 6-amino-2-{2-[[2-(4-amino-butylamino)-acetyl]-(5-amino-pentyl)-amino]-acetylamino}-hexyl ester (Compound DH);

Carbamic acid 6-amino-2-{2-[(2-amino-5-guanidino-pentyloxycarbonyl)-(5-amino-pentyl)-amino]-acetylamino}-hexyl ester (Compound DI);

Carbamic acid 6-amino-2-{2-[(2-amino-4-carbamoyl-butoxycarbonyl)-(S-amino-penty1)-amino]-acetylamino}-hexyl ester (Compound DJ);

Carbamic acid 6-amino-2-{2-[(7-amino-heptyl)-(2,6-diamino-hexyloxycarbonyl)-amino]-acetylamino}-hexyl ester (Compound DK);

Carbamic acid 6-amino-2-{2-[(7-amino-heptyl)-(2,6-diamino-hexyloxycarbonyl)-amino]-acetylamino}-hexyl ester (Compound DL);

Carbamic acid 6-amino-2-{2-[(7-amino-heptyl)-(2,6-diamino-hexanoyl)-amino]-acetylamino}-hexyl ester (Compound DM);

Carbamic acid 6-amino-2-{2-[(7-amino-heptyl)-(2,6-diamino-hexanoyl)-amino]-acetylamino}-hexyl ester (Compound DN);

Carbamic acid 6-amino-2-(2-{(7-amino-heptyl)-[2-(5-amino-pentylamino)-acetyl]-amino}-acetylamino)-hexyl ester (Compound DO);

Carbamic acid 6-amino-2-(2-{(7-amino-heptyl)-[2-(7-amino-heptylamino)-acetyl]-amino}-acetylamino)-hexyl ester (Compound DP);

Carbamic acid 6-amino-2-{2-[[2-(4-amino-butylamino)-acetyl]-(7-amino-heptyl)-amino]-acetylamino}-hexyl ester (Compound DQ);

Carbamic acid 6-amino-2-{2-[(2-amino-5-guanidino-pentyloxycarbonyl)-(7-amino-heptyl)-amino]-acetylamino}-hexyl ester (Compound DR);

Carbamic acid 6-amino-2-{2-[(2-amino-4-carbamoyl-butoxycarbonyl)-(7-amino-heptyl)-amino]-acetylamino}-hexyl ester (Compound DS);

Carbamic acid 6-amino-2-[6-amino-2-(2-amino-5-guanidino-pentyloxycarbonylamino)-hexanoylamino]-hexyl ester (Compound DT);

Carbamic acid 6-amino-2-[6-amino-2-(2-amino-4-carbamoyl-butoxycarbonylamino)-hexanoylamino]-hexyl ester (Compound DU); and pharmaceutically acceptable salts thereof.
5. A compound of formula V:

and pharmaceutically acceptable salts thereof, wherein each R2 is independently selected from the group consisting of -NH2, -NHC(=NH)NH2, -CH2C(=NH)NH2, and -C(O)NH2;
each n is independently an integer ranging from 3 to 7; and each * is an (R) or (S) chiral center.
6. The compound of claim 5, selected from the group consisting of:

1-{5-Amino-1-[3-(1-aminomethyl-4-guanidino-butyl)-ureidomethyl]-pentyl}-3-(5-guanidino-2-ureido-pentyl)-urea(Compound DV);

1-{5-Amino-1-[3-(5-amino-1-aminomethyl-pentyl)-ureidomethyl]-pentyl}-3-(5-guanidino-2-ureido-pentyl)-urea(Compound DW);

1-{1-[3-(5-Amino-1-aminomethyl-pentyl)-ureidomethyl]-4-guanidino-butyl}-3-(5-guanidino-2-ureido-pentyl)-urea (Compound DX);

1-{5-Amino-1-[3-(2-amino-ethyl)-ureidomethyl]-pentyl}-3-(5-guanidino-2-ureido-pentyl)-urea (Compound DY); and pharmaceutically acceptable salts thereof.
7. A composition comprising a therapeutically effective amount of a compound of claim 1.
8. A composition comprising a therapeutically effective amount of a compound of claim 4.
9. The composition of claim 7, further comprising a pharmaceutically acceptable vehicle.
10. The composition of claim 7, further comprising an anticancer agent.
11. The composition of claim 7, further comprising an anti-inflammatory agent.
12. The composition of claim 7, further comprising an antiviral agent.
13. A method for treating or preventing cancer, inflammation, or a viral infection in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 1.
14. A method for treating or preventing cancer, inflammation, or a viral infection in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 4.
15. The method of claim 13, wherein the cancer is selected from the group consisting of leukemia, acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia, chronic leukemia, chronic myelocytic, (granulocytic) leukemia, chronic lymphocytic leukemia, Polycythemia vera, lymphoma, Hodgkin's disease, non-Hodgkin's disease, Multiple myeloma, Waldenström's macroglobulinemia, Heavy chain disease, solid tumors, sarcomas and carcinomas, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, uterine cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, and neuroblastomaretinoblastoma.
16. The method of claim 13, wherein the inflammation is selected from the group consisting of eczema, inflammatory bowel disease, rheumatoid arthritis, asthma, psoriasis, ischemia/reperfusion injury, ulcerative colitis and acute respiratory distress syndrome.
17. The method of claim 13, wherein the viral infection is selected from the group consisting of infections caused by hepatitis B, hepatitis C, rotavirus, human immunodeficiency virus type I(HIV-I), human immunodeficiency virus type II
(HIV-II), human T-cell lymphotropic virus type I(HTLV-I), human T-cell lymphotropic virus type II
(HTLV-II), AIDS, DNA viruses such as hepatitis type B and hepatitis type C
virus;

parvoviruses, such as adeno-associated virus and cytomegalovirus;
papovaviruses such as papilloma virus, polyoma viruses, and SV40; adenoviruses; herpes viruses such as herpes simplex type I(HSV-I), herpes simplex type II(HSV-II), and Epstein-Barr virus;
poxviruses, such as variola (smallpox) and vaccinia virus; and RNA viruses, such as human immunodeficiency virus type I(HIV-I), human immunodeficiency virus type II(HIV-II), human T-cell lymphotropic virus type I(HTLV-I), human T-cell lymphotropic virus type II

(HTLV-II), influenza virus, measles virus, rabies virus, Sendai virus, picornaviruses such as poliomyelitis virus, coxsackieviruses, rhinoviruses, reoviruses, togaviruses such as rubella virus (German measles) and Semliki forest virus, arboviruses, and hepatitis type A virus.
18. A composition comprising a therapeutically effective amount of a compound of claim 5.
19. A composition comprising a therapeutically effective amount of a compound of claim 6.
20. The composition of claim 18, further comprising a pharmaceutically acceptable vehicle.
21. The composition of claim 18, further comprising an anticancer agent.
22. The composition of claim 18, further comprising an anti-inflammatory agent.
23. The composition of claim 18, further comprising an antiviral agent.
24. A method for treating or preventing cancer, inflammation, or a viral infection in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 5.
25. A method for treating or preventing cancer, inflammation, or a viral infection in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of a compound of claim 6.
26. The method of claim 24, wherein the cancer is selected from the group consisting of leukemia, acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia, chronic leukemia, chronic myelocytic, (granulocytic) leukemia, chronic lymphocytic leukemia, Polycythemia vera, lymphoma, Hodgkin's disease, non-Hodgkin's disease, Multiple myeloma, Waldenstrom's macroglobulinemia, Heavy chain disease, solid tumors, sarcomas and carcinomas, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, uterine cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, and neuroblastomaretinoblastoma.
27. The method of claim 24, wherein the inflammation is selected from the group consisting of eczema, inflammatory bowel disease, rheumatoid arthritis, asthma, psoriasis, ischemia/reperfusion injury, ulcerative colitis and acute respiratory distress syndrome.
28. The method of claim 24, wherein the viral infection is selected from the group consisting of infections caused by hepatitis B, hepatitis C, rotavirus, human immunodeficiency virus type I(HIV-I), human immunodeficiency virus type II(HIV-II), human T-cell lymphotropic virus type I(HTLV-I), human T-cell lymphotropic virus type II
(HTLV-II), AIDS, DNA viruses such as hepatitis type B and hepatitis type C
virus;
parvoviruses, such as adeno-associated virus and cytomegalovirus;
papovaviruses such as papilloma virus, polyoma viruses, and SV40; adenoviruses; herpes viruses such as herpes simplex type I(HSV-I), herpes simplex type II(HSV-II), and Epstein-Barr virus;
poxviruses, such as variola (smallpox) and vaccinia virus; and RNA viruses, such as human immunodeficiency virus type I(HIV-I), human immunodeficiency virus type II(HIV-II), human T-cell lymphotropic virus type I(HTLV-I), human T-cell lymphotropic virus type II
(HTLV-II), influenza virus, measles virus, rabies virus, Sendai virus, picornaviruses such as poliomyelitis virus, coxsackieviruses, rhinoviruses, reoviruses, togaviruses such as rubella virus (German measles) and Semliki forest virus, arboviruses, and hepatitis type A virus.
CA002386540A 1999-10-04 2000-10-04 Novel carbamates and ureas Abandoned CA2386540A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15764699P 1999-10-04 1999-10-04
US60/157,646 1999-10-04
PCT/US2000/027398 WO2001025188A1 (en) 1999-10-04 2000-10-04 Novel carbamates and ureas

Publications (1)

Publication Number Publication Date
CA2386540A1 true CA2386540A1 (en) 2001-04-12

Family

ID=22564644

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002386239A Abandoned CA2386239A1 (en) 1999-10-04 2000-10-04 Methods for identifying rna binding compounds
CA002386540A Abandoned CA2386540A1 (en) 1999-10-04 2000-10-04 Novel carbamates and ureas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA002386239A Abandoned CA2386239A1 (en) 1999-10-04 2000-10-04 Methods for identifying rna binding compounds

Country Status (8)

Country Link
US (5) US6420591B1 (en)
EP (3) EP1226115A4 (en)
JP (2) JP2003511362A (en)
AT (1) ATE432993T1 (en)
AU (2) AU7855900A (en)
CA (2) CA2386239A1 (en)
DE (1) DE60042338D1 (en)
WO (2) WO2001025188A1 (en)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056656B1 (en) * 1999-01-25 2006-06-06 University Of Medicine And Dentistry Of New Jersey Tat-derived oligourea and its method of production and use in high affinity and specific binding HIV-1 TAR RNA
US6458538B1 (en) * 1999-12-14 2002-10-01 Ptc Therapeutics, Inc. Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
AU2002211475A1 (en) * 2000-10-04 2002-04-15 University Of Medicine And Dentistry Of New Jersey Site-specific protein modification
WO2002083837A1 (en) * 2001-04-11 2002-10-24 Ptc Therapeutics, Inc. Methods for identifying small molecules that bind specific rna structural motifs
US20060228730A1 (en) * 2001-04-11 2006-10-12 Rando Robert F Methods for identifying small molecules that bind specific RNA structural motifs
CA2381627C (en) * 2001-04-13 2010-06-22 Michael J. Mitrovich Solid lubricant and composition
US20030004143A1 (en) * 2001-04-18 2003-01-02 Prior Christopher P. Use of NSAIDs for prevention and treatment of cellular abnormalities of the female reproductive tract
WO2003056298A2 (en) * 2001-11-06 2003-07-10 Agilix Corporation Sensitive coded detection systems
WO2003062388A2 (en) * 2002-01-16 2003-07-31 The Regents Of The University Of California Inhibition of rna function
US7291461B2 (en) * 2002-06-21 2007-11-06 Ptc Therapeutics, Inc. Methods for identifying small molecules that modulate premature translation termination and nonsense mRNA decay
US20040018495A1 (en) * 2002-07-24 2004-01-29 Xing-Xiang Li Microparticle based signal amplification for the detection of analytes
WO2004010106A2 (en) 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLEDULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
EP2656854B1 (en) * 2003-02-04 2015-05-20 Cornell Research Foundation, Inc. Uses of aromatic-cationic peptide
EP2319318A3 (en) * 2003-03-27 2011-08-17 PTC Therapeutics, Inc. Methods of identifying compounds that target TRNA splicing endonuclease and uses of said compounds as anti-proliferative agents
US7829503B2 (en) 2003-03-27 2010-11-09 Ptc Therapeutics, Inc. Methods of identifying compounds that target tRNA splicing endonuclease and uses of said compounds as anti-fungal agents
CA2520664A1 (en) * 2003-03-27 2004-10-14 Ptc Therapeutics, Inc. Targeting enzymes of the trna splicing pathway for identification of anti-fungal and/or anti-proliferative molecules
DK1625149T3 (en) 2003-05-01 2016-05-30 Cornell Res Foundation Inc METHOD AND carrying complexes for delivery of molecules to cells
EP1656443A4 (en) * 2003-05-02 2007-06-06 Sigma Aldrich Co Solid phase cell lysis and capture platform
EP1649002A4 (en) * 2003-07-02 2009-06-03 Ptc Therapeutics Inc Rna processing protein complexes and uses thereof
US20050064470A1 (en) * 2003-07-17 2005-03-24 Rana Tariq M. High throughput screening methods for identifying RNA binding compounds
AU2005267607B8 (en) * 2003-09-11 2009-07-16 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
AU2004273076B2 (en) * 2003-09-11 2008-02-14 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
EP1709447B1 (en) * 2003-12-18 2009-06-24 Idexx Laboratories, Inc. Method for detecting feline immunodeficiency virus
RU2376028C2 (en) * 2004-01-23 2009-12-20 Корнелл Рисеч Фаундейшн, Инк. Method for reduction of oxidising injury (versions)
US20050186606A1 (en) * 2004-02-11 2005-08-25 Schroeder Benjamin G. Methods and compositions for detecting nucleic acids
US20060069050A1 (en) * 2004-02-17 2006-03-30 University Of Massachusetts Methods and compositions for mediating gene silencing
ATE504834T1 (en) * 2004-02-19 2011-04-15 Idexx Lab Inc METHOD AND DEVICE FOR DETECTING CAT IMMUNE DEFICIENCY VIRUS
GB0410103D0 (en) * 2004-05-06 2004-06-09 Biolipox Ab New method
CA2570610A1 (en) * 2004-06-30 2006-02-02 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
JP4866848B2 (en) * 2004-06-30 2012-02-01 アイデックス ラボラトリーズ インコーポレイテッド Methods and apparatus for detecting FIV comprising the use of peptides derived from the V3 region of the ENV protein of feline immunodeficiency virus (FIV)
WO2006026248A1 (en) * 2004-08-25 2006-03-09 Sigma-Aldrich Co. Compositions and methods employing zwitterionic detergent combinations
WO2006091459A2 (en) * 2005-02-24 2006-08-31 Joslin Diabetes Center, Inc. Compositions and methods for treating vascular permeability
US7291338B2 (en) * 2005-03-09 2007-11-06 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
KR100780405B1 (en) 2005-08-31 2007-11-28 재단법인서울대학교산학협력재단 A Process for screening of a binding peptides specific for specific RNA and RNA binding peptides therefrom
US20070134685A1 (en) * 2005-09-06 2007-06-14 Invitrogen Corporation Control of chemical modification
CN103784937B (en) * 2005-09-16 2017-04-26 科内尔研究基金会 Methods for reducing CD36 expression
WO2008024858A2 (en) * 2006-08-22 2008-02-28 University Of Virginia Patent Foundation Methods and compounds regulating the erythroid response to iron deficiency
WO2008024499A2 (en) * 2006-08-25 2008-02-28 Duke University Methods for in vivo identification of endogenous mrna targets of micrornas
US7598040B2 (en) 2006-11-22 2009-10-06 Trana Discovery, Inc. Compositions and methods for the identification of inhibitors of protein synthesis
US7795457B2 (en) * 2007-02-26 2010-09-14 Kosan Biosciences Incorporated Carbamate compounds
CN101754682B (en) 2007-05-16 2014-11-12 布里格姆妇女医院 Treatment of synucleinopathies
US7964843B2 (en) 2008-07-18 2011-06-21 The George Washington University Three-dimensional molecular imaging by infrared laser ablation electrospray ionization mass spectrometry
US8901487B2 (en) 2007-07-20 2014-12-02 George Washington University Subcellular analysis by laser ablation electrospray ionization mass spectrometry
US8067730B2 (en) 2007-07-20 2011-11-29 The George Washington University Laser ablation electrospray ionization (LAESI) for atmospheric pressure, In vivo, and imaging mass spectrometry
US20110033850A1 (en) * 2007-09-14 2011-02-10 Agris Paul F Compositions and methods for the identification of inhibitors of retroviral infection
JP5600064B2 (en) 2007-10-26 2014-10-01 アカデミシュ ジーケンハウス ライデン Means and methods for offsetting myopathy
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
US8530182B2 (en) * 2007-12-05 2013-09-10 Centers For Disease Control And Prevention Viral protein quantification process and vaccine quality control therewith
US8673884B2 (en) * 2008-02-05 2014-03-18 Versitech Limited Anti-influenza compounds
CN101939019B (en) 2008-02-07 2014-07-16 康奈尔大学 Methods for preventing or treating insulin resistance
CN104056248A (en) 2008-02-26 2014-09-24 康奈尔大学 Methods For Prevention And Treatment Of Acute Renal Injury
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
US20110208064A1 (en) 2008-07-31 2011-08-25 Ran Chongzhao Curcumin Derivatives for Amyloid-Beta Plaque Imaging
CA2776044A1 (en) * 2008-09-29 2010-04-01 Trana Discovery, Inc. Screening methods for identifying specific staphylococcus aureus inhibitors
ES2562658T3 (en) 2008-10-27 2016-03-07 Biomarin Technologies B.V. Procedures and means for efficient skipping of exon 45 in the pre-mRNA of Duchenne muscular dystrophy
EA202090636A3 (en) 2009-02-13 2021-04-30 Икс-Чем, Инк. METHODS FOR CREATING AND SCREENING DNA-CODED LIBRARIES
EP3563862B1 (en) * 2009-03-20 2021-05-05 The General Hospital Corporation d/b/a Massachusetts General Hospital D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention of secondary complications of burn injuries
CN102573847A (en) 2009-05-14 2012-07-11 总医院公司 Methods and compositions for treating degenerative and ischemic disorders
US9149024B2 (en) 2009-06-22 2015-10-06 Massachusetts Eye & Ear Infirmary Islet1 (Isl1) and hearing loss
WO2011019809A1 (en) * 2009-08-12 2011-02-17 Cornell University Methods for preventing or treating metabolic syndrome
EP3292868A1 (en) 2009-08-24 2018-03-14 Stealth Peptides International, Inc. Methods and compositions for preventing or treating opthalmic conditions
CA2776581C (en) 2009-10-05 2020-12-15 Cornell University Methods for the prevention or treatment of heart failure
EP2553452B1 (en) 2010-04-02 2015-03-04 IDEXX Laboratories, Inc. Detection of feline immunodeficiency virus
US20190300945A1 (en) 2010-04-05 2019-10-03 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
EP3034625B1 (en) 2010-10-21 2017-10-04 Advanced Cell Diagnostics, Inc. An ultra sensitive method for in situ detection of nucleic acids
US20130288364A1 (en) * 2010-10-28 2013-10-31 Whitehead Institute For Biomedical Research Engineered kinetochores and uses thereof
CN103619879A (en) 2010-12-01 2014-03-05 奥尔德生物控股有限责任公司 Anti-ngf compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
GB201106254D0 (en) 2011-04-13 2011-05-25 Frisen Jonas Method and product
AU2012267786B2 (en) 2011-06-10 2017-08-03 Oregon Health & Science University CMV glycoproteins and recombinant vectors
EP2732457A4 (en) 2011-07-14 2015-09-16 Univ George Washington Plume collimation for laser ablation electrospray ionization mass spectrometry
DK2753694T3 (en) 2011-09-05 2017-10-16 Stichting Katholieke Univ Antisense oligonucleotides for the treatment of Leber Congenital Amaurosis
KR102242879B1 (en) 2011-09-07 2021-04-20 엑스-켐, 인크. Methods for tagging dna-encoded libraries
JP2015508407A (en) 2012-01-06 2015-03-19 アビデ セラピューティクス,インク. Carbamate compounds and their manufacture and use
WO2013112053A1 (en) 2012-01-27 2013-08-01 Prosensa Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
US9534059B2 (en) 2012-04-13 2017-01-03 Children's Medical Center Corporation TIKI inhibitors
CN104685115A (en) 2012-07-13 2015-06-03 X-化学有限公司 DNA-encoded libraries having encoding oligonucleotide linkages not readable by polymerases
WO2014025808A1 (en) 2012-08-06 2014-02-13 The General Hospital Corporation Curcumin analogs
SG11201507366RA (en) 2013-03-15 2015-10-29 Gen Hospital Corp Glycine, mitochondrial one-carbon metabolism, and cancer
MX2015016963A (en) 2013-06-10 2016-08-08 Dana Farber Cancer Inst Inc Methods and compositions for reducing immunosupression by tumor cells.
WO2014210225A1 (en) 2013-06-25 2014-12-31 Prognosys Biosciences, Inc. Methods and systems for determining spatial patterns of biological targets in a sample
US9757477B2 (en) 2013-09-06 2017-09-12 The General Hospital Corporation Imaging brown adipose tissue with curcumin derivatives
WO2015187938A1 (en) 2014-06-05 2015-12-10 The Brigham And Women's Hospital, Inc. Diagnosis and treatment of invasive aspergillosis
AU2015286663B2 (en) 2014-07-10 2021-09-23 Stichting Radboud Universitair Medisch Centrum Antisense oligonucleotides for the treatment of usher syndrome type 2
CA2966044A1 (en) 2014-10-30 2016-05-06 The General Hospital Corporation Methods for modulating atrx-dependent gene repression
US9771341B2 (en) 2015-03-18 2017-09-26 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
EP3901282B1 (en) 2015-04-10 2023-06-28 Spatial Transcriptomics AB Spatially distinguished, multiplex nucleic acid analysis of biological specimens
SG10202012002TA (en) 2015-05-11 2021-01-28 Lundbeck La Jolla Research Center Inc Methods of treating inflammation or neuropathic pain
WO2016210241A1 (en) 2015-06-26 2016-12-29 Beth Israel Deaconess Medical Center, Inc. Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
WO2017066712A2 (en) 2015-10-16 2017-04-20 The Children's Medical Center Corporation Modulators of telomere disease
WO2017066796A2 (en) 2015-10-16 2017-04-20 The Children's Medical Center Corporation Modulators of telomere disease
US11466252B2 (en) 2016-01-29 2022-10-11 Massachusetts Eye And Ear Infirmary Expansion and differentiation of inner ear supporting cells and methods of use thereof
WO2017143283A1 (en) 2016-02-19 2017-08-24 Abide Therapeutics, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
CN109072239A (en) 2016-04-25 2018-12-21 ProQR治疗上市公司Ⅱ The oligonucleotides for treating eye disease
WO2017197386A1 (en) 2016-05-13 2017-11-16 The Brigham And Women's Hospital, Inc. Volatile metabolite profiles for the diagnosis and treatment of mucorales fungi
WO2017218355A1 (en) 2016-06-15 2017-12-21 Counterpoint Biomedica Llc Polypeptide targeting aptamers for characterization, capture, and clinical management of circulating tumor cells
EP3479102A1 (en) * 2016-07-04 2019-05-08 CellTool GmbH Device and method for the determination of transfection
WO2018053447A1 (en) 2016-09-19 2018-03-22 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
JOP20190106A1 (en) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc Magl inhibitors
JOP20190105A1 (en) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc Magl inhibitors
KR20200057071A (en) * 2017-09-25 2020-05-25 스카이호크 테라퓨틱스, 인코포레이티드 Methods and compositions for screening and identification of splicing modulators
PE20211385A1 (en) 2018-05-15 2021-07-27 Lundbeck La Jolla Research Center Inc MAGL INHIBITORS
US11519033B2 (en) 2018-08-28 2022-12-06 10X Genomics, Inc. Method for transposase-mediated spatial tagging and analyzing genomic DNA in a biological sample
US11649485B2 (en) 2019-01-06 2023-05-16 10X Genomics, Inc. Generating capture probes for spatial analysis
US11926867B2 (en) 2019-01-06 2024-03-12 10X Genomics, Inc. Generating capture probes for spatial analysis
CN113660980A (en) 2019-02-07 2021-11-16 通用医疗公司 Carotenoids for use in the treatment or prevention of nausea
WO2021092433A2 (en) 2019-11-08 2021-05-14 10X Genomics, Inc. Enhancing specificity of analyte binding
EP4055185A1 (en) 2019-11-08 2022-09-14 10X Genomics, Inc. Spatially-tagged analyte capture agents for analyte multiplexing
AU2020412766A1 (en) 2019-12-23 2022-06-09 10X Genomics, Inc. Methods for spatial analysis using RNA-templated ligation
US11702693B2 (en) 2020-01-21 2023-07-18 10X Genomics, Inc. Methods for printing cells and generating arrays of barcoded cells
US11732299B2 (en) 2020-01-21 2023-08-22 10X Genomics, Inc. Spatial assays with perturbed cells
US11821035B1 (en) 2020-01-29 2023-11-21 10X Genomics, Inc. Compositions and methods of making gene expression libraries
US11898205B2 (en) 2020-02-03 2024-02-13 10X Genomics, Inc. Increasing capture efficiency of spatial assays
US11732300B2 (en) 2020-02-05 2023-08-22 10X Genomics, Inc. Increasing efficiency of spatial analysis in a biological sample
US11835462B2 (en) 2020-02-11 2023-12-05 10X Genomics, Inc. Methods and compositions for partitioning a biological sample
US11891654B2 (en) 2020-02-24 2024-02-06 10X Genomics, Inc. Methods of making gene expression libraries
US11926863B1 (en) 2020-02-27 2024-03-12 10X Genomics, Inc. Solid state single cell method for analyzing fixed biological cells
US11768175B1 (en) 2020-03-04 2023-09-26 10X Genomics, Inc. Electrophoretic methods for spatial analysis
US11702393B2 (en) 2020-04-21 2023-07-18 H. Lundbeck A/S Synthesis of a monoacylglycerol lipase inhibitor
CN115916999A (en) 2020-04-22 2023-04-04 10X基因组学有限公司 Methods for spatial analysis using targeted RNA depletion
WO2021237087A1 (en) 2020-05-22 2021-11-25 10X Genomics, Inc. Spatial analysis to detect sequence variants
EP4153775A1 (en) 2020-05-22 2023-03-29 10X Genomics, Inc. Simultaneous spatio-temporal measurement of gene expression and cellular activity
WO2021242834A1 (en) 2020-05-26 2021-12-02 10X Genomics, Inc. Method for resetting an array
WO2021247543A2 (en) 2020-06-02 2021-12-09 10X Genomics, Inc. Nucleic acid library methods
AU2021283184A1 (en) 2020-06-02 2023-01-05 10X Genomics, Inc. Spatial transcriptomics for antigen-receptors
EP4162074A1 (en) 2020-06-08 2023-04-12 10X Genomics, Inc. Methods of determining a surgical margin and methods of use thereof
WO2021252591A1 (en) 2020-06-10 2021-12-16 10X Genomics, Inc. Methods for determining a location of an analyte in a biological sample
WO2021263111A1 (en) 2020-06-25 2021-12-30 10X Genomics, Inc. Spatial analysis of dna methylation
US11761038B1 (en) 2020-07-06 2023-09-19 10X Genomics, Inc. Methods for identifying a location of an RNA in a biological sample
US11926822B1 (en) 2020-09-23 2024-03-12 10X Genomics, Inc. Three-dimensional spatial analysis
US11827935B1 (en) 2020-11-19 2023-11-28 10X Genomics, Inc. Methods for spatial analysis using rolling circle amplification and detection probes
WO2022140028A1 (en) 2020-12-21 2022-06-30 10X Genomics, Inc. Methods, compositions, and systems for capturing probes and/or barcodes
EP4301870A1 (en) 2021-03-18 2024-01-10 10X Genomics, Inc. Multiplex capture of gene and protein expression from a biological sample
WO2023034489A1 (en) 2021-09-01 2023-03-09 10X Genomics, Inc. Methods, compositions, and kits for blocking a capture probe on a spatial array
WO2023183887A2 (en) * 2022-03-23 2023-09-28 Duke University Compositions for and methods of modulating rna stability

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
DE3785591T2 (en) 1986-01-10 1993-09-02 Amoco Corp COMPETITIVE HOMOGENEOUS TEST.
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
AU3249793A (en) * 1991-12-24 1993-07-28 Isis Pharmaceuticals, Inc. Compositions and methods for modulating beta -amyloid
US5721099A (en) * 1992-10-01 1998-02-24 Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
JP3394777B2 (en) 1993-05-27 2003-04-07 セレクタイド コーポレーション Topologically separated, encoded solid-phase library
AU7562594A (en) * 1993-08-18 1995-03-14 Board Of Trustees Of The Leland Stanford Junior University Sequence-specific glycoconjugate transcriptional antagonists
CA2180844A1 (en) * 1994-01-13 1995-07-20 W. Clark Still Synthetic receptors, libraries and uses thereof
US5712096A (en) * 1994-08-23 1998-01-27 University Of Massachusetts Medical Center Oligoribonucleotide assays for novel antibiotics
US5627210A (en) * 1995-02-06 1997-05-06 Chiron Corporation Branched combinatorial libraries
US5593835A (en) * 1995-05-12 1997-01-14 President And Fellows Of Harvard College Methods and kits for RNA binding compounds
WO1997009342A1 (en) 1995-09-08 1997-03-13 Scriptgen Pharmaceuticals, Inc. Screen for compounds with affinity for rna
US5666341A (en) * 1995-09-18 1997-09-09 Matsushita Electric Industrial Co., Ltd. Data detection apparatus
US5866341A (en) * 1996-04-03 1999-02-02 Chugai Pharmaceutical Co., Ltd. Compositions and methods for screening drug libraries
US6107029A (en) 1996-07-31 2000-08-22 Message Pharmaceticals, Inc. Universal method for detecting interactions between RNA molecules and RNA binding proteins
US6004749A (en) 1996-07-31 1999-12-21 Message Pharmaceuticals Method for identifying compounds affecting RNA/RNA binding protein interactions
US5843995A (en) 1997-07-07 1998-12-01 University Of Medicine And Dentistry Of New Jersey Inhibition of HIV-1 replication using oligocarbamate derivatives
EP1030925A1 (en) * 1997-11-12 2000-08-30 Brigham & Women's Hospital, Inc. The translation enhancer element of the human amyloid precursor protein gene

Also Published As

Publication number Publication date
ATE432993T1 (en) 2009-06-15
EP2071036A2 (en) 2009-06-17
AU7856600A (en) 2001-05-10
EP1226115A4 (en) 2006-03-15
EP1226115A1 (en) 2002-07-31
EP1218544A4 (en) 2005-05-25
WO2001025188A1 (en) 2001-04-12
US20050221368A1 (en) 2005-10-06
US6503713B1 (en) 2003-01-07
US20030153523A1 (en) 2003-08-14
WO2001025486A1 (en) 2001-04-12
DE60042338D1 (en) 2009-07-16
EP1218544B1 (en) 2009-06-03
US6420591B1 (en) 2002-07-16
EP2071036A3 (en) 2009-09-09
AU7855900A (en) 2001-05-10
US6875736B2 (en) 2005-04-05
EP1218544A1 (en) 2002-07-03
US6583309B1 (en) 2003-06-24
JP2003511045A (en) 2003-03-25
JP2003511362A (en) 2003-03-25
CA2386239A1 (en) 2001-04-12

Similar Documents

Publication Publication Date Title
US6420591B1 (en) Carbamates and compositions thereof, and methods for their use for treating cancer, inflammation, or a viral infection
JP5680577B2 (en) Combinatorial synthesis of macrocyclic compound libraries useful for drug discovery
CA2183428A1 (en) Sulfonamide derivatives and their use
JPH03118357A (en) Novel peptidase and isomerase inhibitor
US5545640A (en) Protease inhibiting succinic acid derivatives
NO178541B (en) Pharmacologically active hydrazine derivatives
CA3024071C (en) Libraries of diverse macrocyclic compounds and methods of making and using the same
EP1140822A1 (en) Stable activated novel carbamic acid derivatives, preparation method and use for preparing urea
TW201011031A (en) Nitrogenated derivatives of pancratistatin
CA3023854A1 (en) Novel 2,4,6-trisubstituted s-triazine compounds, preparation method therefor, and use thereof
US6525182B1 (en) Guanidinylation, guanidinoglycosides, uses, and methods of assaying their activity
JPH11508919A (en) Arylacrylic acid derivatives useful as protein tyrosine phosphatase inhibitors
US7999101B2 (en) Cationic lipids for the transfection of nucleic acids
US6452050B1 (en) Synthesis and use of α-ketoamide derivatives and arrays
KR0125104B1 (en) Novel hiv protease inhibitors and the processes for preparation thereof
CA2217030C (en) Protease inhibiting succinic acid derivatives
Babu et al. Zinc promoted rapid and efficient synthesis of Fmoc-and Z-α, α-dialkylamino acids under neutral conditions
Foulds Biologically active peptide analogues

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20061004